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ABSTRACT OF THE DISSERTATION 
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        I proposed the study of two distinct aspects of Ten-Eleven Translocation 2 (TET2) 
protein for understanding specific functions in different body systems. 
        In Part I, I characterized the molecular mechanisms of Tet2 in the hematological 
system. As the second member of Ten-Eleven Translocation protein family, TET2 is 
frequently mutated in leukemic patients. Previous studies have shown that the TET2 
mutations frequently occur in 20% myelodysplastic syndrome/myeloproliferative 
neoplasm (MDS/MPN), 10% T-cell lymphoma leukemia and 2% B-cell lymphoma 
leukemia. Genetic mouse models also display distinct phenotypes of various types of 
hematological malignancies. I performed 5-hydroxymethylcytosine (5hmC) chromatin 
immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq) of 
hematopoietic stem/progenitor cells to determine whether the deletion of Tet2 can affect 
the abundance of 5hmC at myeloid, T-cell and B-cell specific gene transcription start 
sites, which ultimately result in various hematological malignancies. Subsequent Exome 
 vii
sequencing (Exome-Seq) showed that disease-specific genes are mutated in different 
types of tumors, which suggests that TET2 may protect the genome from being mutated. 
The direct interaction between TET2 and Mutator S Homolog 6 (MSH6) protein suggests 
TET2 is involved in DNA mismatch repair. Finally, in vivo mismatch repair studies show 
that the loss of Tet2 causes a mutator phenotype. Taken together, my data indicate that 
TET2 binds to MSH6 to protect genome integrity. 
        In Part II, I intended to better understand the role of Tet2 in the nervous system. 5-
hydroxymethylcytosine regulates epigenetic modification during neurodevelopment and 
aging. Thus, Tet2 may play a critical role in regulating adult neurogenesis. To examine 
the physiological significance of Tet2 in the nervous system, I first showed that the 
deletion of Tet2 reduces the 5hmC levels in neural stem cells. Mice lacking Tet2 show 
abnormal hippocampal neurogenesis along with 5hmC alternations at different gene 
promoters and corresponding gene expression downregulation. Through the luciferase 
reporter assay, two neural factors Neurogenic differentiation 1 (NeuroD1) and Glial 
fibrillary acidic protein (Gfap) were down-regulated in Tet2 knockout cells. My results 
suggest that Tet2 regulates neural stem/progenitor cell proliferation and differentiation in 
adult brain. 
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1.1  DNA METHYLATION AND DEMETHYLATION 
        Epigenetics, proposed by Waddington in 1942, is broadly defined and attributed to 
heritable cellular changes without altering the deoxyribonucleic acid (DNA) sequence1,2. 
Molecular mechanisms of epigenetic regulation include: DNA methylation, histone 
modifications and noncoding regulatory ribonucleic acids (RNAs). DNA methylation on 
cytosine-phosphate-guanine (CpG) islands at promoter regions is considered as one stable 
epigenetic mark3 and such DNA alternation is sufficient to maintain genome imprinting 
and X-chromosome inactivation4. Deoxyribonucleic acid methylation also occurs in other 
genomic elements such as gene body, enhancer and untranslated regions (UTR). It may 
contribute to transcription elongation or gene activation/inactivation5. Histone 
modifications widely exist posttranslationally, and include lysine and arginine 
methylation, lysine acetylation, ubiquitination and sumoylation, as well as serine and 
threonine phosphorylation6. These modifications regulate gene expression and are 
responsible for the presence of enhancers or repressors6,7. In mammalian cells, 
microRNAs regulate gene expression by posttranslational repression of target sequences. 
Since the expression of microRNAs is also affected by their promoter status, the 
transcriptional regulation by microRNAs is relatively mild8. In recent years, studies on 
hematological malignancies have revealed a subset of epigenetic regulators as cancer-
relevant genes. The corresponding epigenetic alterations lead to changes in specific gene 
transcriptions, which finally result in abnormal hematopoietic stem cells (HSC) and/or 
hematopoietic progenitor cells (HPC) self-renewal, proliferation and differentiation. 
        Methylation of DNA normally indicates modification of cytosine. In mammals, the 
DNA methyltransferase (DNMT) family comprises five members: DNMT1, DNMT2, 
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DNMT3A, DNMT3B and DNMT3L. The enzyme DNA methyltransferase 1 (DNMT1) 
maintains cytosine hemimethylated during DNA replication9 (Figure 1). DNA 
methyltransferase 2 (DNMT2), also termed TRDMT1, is the smallest DNMT whose 
function is still poorly understood, but the specific protein structure of DNMT2 suggests 
the possibility of involvement in DNA recombination and DNA damage repair10.  
Deoxyribonucleic acid methyltransferase 3 has two family members: DNMT3A and 
DNMT3B which control de novo cytosine methylation of unmethylated DNA substrates11 
(Figure 1). However, their enzymatic activities can be negatively regulated by DNMT3L, 
which functions mainly during early embryogenesis12,13.  
        The human genome contains around 28 million CpGs while the mouse genome has 
approximately 22 million CpGs. These CpGs reside in different genomic elements such 
as CpG islands (CGIs), gene bodies and enhancers. Only around 20% of CpGs are 
dynamic, most of the CpGs are relatively stable14,15. Genome-wide methylation studies 
have revealed detailed architectural profiles for DNA methylation at gene bodies, CGIs, 
CGI shore, enhancers, canyons, repeats and large differentially methylated regions 
(DMR)16 (Figure 2). Cytosine-phosphate-guanine islands are defined as short and CpG-
rich regions within the genome, and more than 70% of genes have CGIs17. When CGIs 
are unmethylated at the promoter region, that usually signifies transcription initiation in 
nucleosome-free style, in which the transcriptional levels are regulated by Histone H3 
lysine4 tri-methylation and transcription factors association. Whereas, methylation at 
CGIs may signify long-term gene silencing, as occurs in imprinted genes18,19.  
        Recently, genome-wide methylome studies have allowed scientists to examine DNA 
methylation status outside promoter CGIs in both stem and differentiated cells. It has 
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been reported that tissue- or cancer-specific differentially methylated regions within CGI 
shores are more dynamic than those regions within CGIs16. Thus, it is plausible to 
propose that the methylation status at CGI shores may be involved in epigenetic 
reprogramming and cancer20. Actually, many genes in lymphoid- or myeloid-specific 
lineages show frequent methylation changes in CGI shores during cell differentiation21.  
        DNA methylation also occurs in intergenic regions, but little is known about its 
physiological function. As a critical genetic element, most enhancers reside in such 
regions. Studies suggest that cell-specific transcription is closely associated with 
enhancer methylation levels even if the relevant promoter stays unmethylated. Through 
binding to chromatin modulating factors, these enhancers are able to interact with distal 
promoters, which result in specific DNA methylation patterns in different cell types22. 
Genome-wide methylome studies also identify a bunch of differential methylated regions 
that are enriched at different cellular stages during hematopoiesis and these regions are 
demonstrated as transcription factor binding sites. Interestingly, in lymphoid 
stem/progenitor cells, myeloid transcription factor binding sites are hypomethylated. 
Whereas during lymphoid differentiation, myeloid-specific factors binding sites are 
hypermethylated23.  
        In addition, large hypomethylated regions have been identified serendipitously, 
during the process of comparing 5mC abundance in differentiated fibroblasts and human 
embryonic stem cells24. These large canyon regions usually spin at 1Mb, and include 
certain oncogenes and cancer biomarker genes25. The loss of DNA methylation in these 
regions leads to repressive histone mark acquisition and gene downregulation26. 
Moreover, methylation canyons are found in regions with very low levels of methylation 
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in hematopoietic stem cells27. The loss of DNMT3A causes DNA methylation alterations 
at the edge of canyons28. The methylation changes in canyons may result in transcription 
alteration and genomic instability that contribute to the progression of cancer. 
        In addition to being in promoter regions, CGIs are also found within gene bodies16. 
Even though there is a small amount of evidence that gene body methylation correlates 
with gene transcription repression, the opposite, gene transcription activation has been 
proposed29. Indeed, actively transcribed genes have been identified as hypermethylated in 
the gene bodies16. Several studies infer that gene body methylation regions are the 
enhancer sites or regulate tissue-specific gene transcription from promoters. Besides, 
DNA methylation at gene bodies may also facilitate the recruitment of CpG binding 
proteins and prevent CCCTC-binding factor mediated RNA polymerase II stalling and 
spliceosome assembly30-33. Obviously, gene body methylation and promoter methylation 
play distinct roles in transcription regulation. But, the underlying mechanism of gene 
body methylation still needs to be elucidated in the future16. 
        There are also specific genomic regions called repetitive elements with multiple 
copies in the genome. Methylation of repetitive elements may repress the expression of 
transposable elements in order to maintain genome integrity34. Bisulfite sequencing from 
DNMT3B mutant patients exhibit significant changes of DNA methylation in inactive 
heterochromatic regions, satellite repeats and transposons. And, aberrant expression 
levels of key genes may result from hypomethylation of repetitive elements, even though 
ribosomal RNA repeats are free from global hypomethylation35. As the most abundant 
genes in the genome, ribosomal DNA stays in tandem repetitive clusters. The 
hematopoietic progenitor cells from MDS patients harbor increased ribosomal DNA 
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(rDNA) methylation levels with decreased ribosomal RNA (rRNA) expression compared 
to healthy controls35. When myeloid cells are treated with 5-Aza-2′-deoxycytidine, 
significant methylation decrease at rDNA promoter regions is observed along with 
increased rRNA levels36.  
        It has been reported that about 80% of CpGs are methylated in mammalian genome, 
which suggest a relatively stable pattern of DNA methylation in the genome. However, 
DNA methylation can be erased passively or actively through different demethylation 
pathways. Passive demethylation initiates through the inactivation of DNMT1/3 
(downregulation of gene expression, genetic mutations or inhibitors). The methylation of 
a newly synthesized DNA strand is blocked during DNA replication. Other studies have 
demonstrated that DNA methylation patterns can be further modified by active 
demethylation. Active demethylation is mediated by TET family enzymes, which 
catalyze the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) 
and further 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in this pathway37-39 
(Figure 1). 
        On the basis of DNA semiconservative replication mechanism, the relative amount 
of DNA methylation is half diluted when new DNA strands are synthesized. Thus, the 
methylation status at specific gene loci will disappear in daughter cells upon cell 
divisions. The above phenotype is the so-called “passive DNA demethylation”40 (Figure 
1). However, how “active DNA demethylation” initiates is still less understood. Yet, the 
identification of 5mC glycosylases in plants has thrown some light on the process, since 
there is a similar occurrence in mammalian cells during zygote fertilization40,41. In 
primordial germ cells (PGCs), genome-wide erasure of DNA methylation occurs 
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naturally42. It is believed that active DNA demethylation preferentially happens at the 
specific loci in differentiated somatic cells43. Studies on identification of DNA 
demethylases have greatly increased in recent years. Methyl-CpG binding domain protein 
2 (MBD2) binds the promoter region enriched in CpG and functions as a mediator of 
methylation signals to activate gene transcription44. Additional studies have shown that 
mammalian thymine DNA glycosylase (TDG) catalyzes the glycosylation of 5mC, 
eventhough no in vivo data have verified the exact role of TDG in DNA demethylation45. 
But, several potential mechanisms have also been proposed to better explain DNA 
demethylation. These include deamination by activation-induced deaminases (AID), and 
apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) protein 
deaminases or DNMTs. Briefly, generated T:G mismatch leads to the initiation of base 
excision repair (BER) and a series of enzymes facilitate the refill of unmodified 
mononucleotides46. Indeed, several reports provide evidence to support BER mechanisms, 
such as the requirement of BER-related enzymes and low methylation levels in AID 
deficient PGCs47,48. Even if AID is completely eliminated, demethylation of PGCs still 
occurs, suggesting the existence of other possible DNA demethylation mechanisms. 
1.2  5-HYDROXYMETHYLCYTOSINE AND TET FAMILY PROTEINS 
        The first discovery of 5hmC was reported in frog and rodent brain DNA in 1971, but 
this amazing finding did not draw too much attention49. In 2009, two labs shed light on 
the mystery nucleotide in mammalian DNA (Figure 3&4). Kriaucionis and Heintz (2009) 
detected an unusual nucleotide when comparing the abundance of 5mC in cerebellar 
Purkinje neurons and granule cells38. Subsequent experiments determined the nucleotide 
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as 5hmC, but the abundance of 5hmC is quite low with less than 1% of total nucleotides 
in cerebellar Purkinje neurons and granule cells38 (Figure 4). In another study, Rao and 
colleagues (2009) showed that the Ten Eleven Translocation (TET) family proteins 
catalyze the conversion of 5mC to 5hmC (Figure 5), suggesting a novel epigenetic 
regulation of 5hmC37. In addition, 5hmC expression level was found to be higher in 
mouse embryonic stem cells (mESC) than other cell types. Both Tet1 and 5hmC levels 
are downregulated upon the differentiation of mESC, suggesting a potential role of Tet1 
and 5hmC in epigenetic reprogramming37. The recurrence of 5hmC has caught the 
interest of many towards providing detailed characterization of its biological functions. 
Ten Eleven Translocation 1 protects the promoter region of Nanog in an unmethylated 
state, which regulates ESC self-renewal and lineage commitment. Once Tet1 is knocked 
down, the promoter of Nanog returns to a methylated state and finally contributes to gene 
silencing. In contrast, the overexpression of Tet1 triggers the demethylation of 
methylated plasmid DNA50. 
        In various human and mouse cells, 5hmC displays differential profiles, suggesting a 
critical balance between 5mC and 5hmC, which may subsequently maintain the cell in its 
normal state37,38,51. Except for serving as an intermediate during active DNA 
demethylation, 5hmC may have other functions in biological systems. The base-
resolution level of 5hmC helps to uncover its biological roles. Several techniques have 
been developed to map 5hmC architecture in the genome. These techniques include 
cytosine-5-methylenesulfonate sequencing, oxidative bisulfate sequencing, 
hydroxymethyl DNA immunoprecipitation sequencing and Tet2-assisted bisulfite 
sequencing52-56 (Figure 6). Studies using these techniques have characterized 5hmC 
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profiles in different cells and tissues. For example, 5hmC accounts for 1% of total 5mC 
in immune cells, 5-10% of total 5mC in ES cells and 40% of total 5mC in neural 
cells37,38,57. Whereas, 5fC and 5ca represent only 0.03% and 0.01% of total 5mC in mouse 
ES cells39. Analysis of genome-wide Tet1-dependent 5hmC distribution, has shown that 
Tet1 and Tet1-dependent 5hmC are enriched at transcription start sites (TSS) along with 
repressive histone modifications58,59. However, other labs have obtained opposite results, 
in which 5hmC and histone modifications are enriched at enhancers, promoters and exons 
in order to regulate active transcription60-62. These differences are plausible for 
independent mechanisms, different techniques and the variation of 5hmC dynamics from 
cell to cell during 5hmC signal capture. In addition, 5hmC abundance changes 
dynamically during human CD34+ cell and erythroid development such that 5hmC 
increases at erythroid-specific transcription factor binding sites and decreases at 
repressive genes. Also, rapid DNA demethylation is observed during erythropoiesis63,64. 
Therefore, it is reasonable to assert that 5hmC regulates transcription activation or 
repression during cell differentiation. The later discovery of TET family proteins has 
helped to better understand the importance of 5hmC and 5hmC dynamics in gene 
expression and cell-fate decision. 
        Ten-eleven translocation (TET) family proteins contain two key components: Fe (II) 
and 2-oxoglutarate (2-OG) to catalyze oxidation of the methyl group of 5mC to 
hydroxymethyl, formyl and carboxyl groups, which generate 5-hydroxymethylcytosine, 
5-formylcytosine and 5-carboxylcytosine step-by-step in an enzymatic activity-dependent 
manner39,65. Presently, the biological functions of 5hmC, 5fC and 5caC are not well-
studied, but most of recent studies have pointed potential roles to DNA demethylation, 
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which regulates gene expression by a series of enzyme catalysis and DNA repair 
mechanisms3. All three family members of TET: TET1, TET2 and TET3 are present in 
different mammalian tissues57. They participate in diverse biological processes, i.e., gene 
transcription, embryonic development and cancer initiation/progression.  
        The discovery of TET proteins originate from analysis of J-binding-protein 1 (JBP1) 
and JBP2 in the parasite Trypanosoma brucei that causes African sleeping sickness66. 
Such species contain base J, a modified thymine in which β-D-glucosyl-hydroxymethyl 
group is added up to uracil, which enzymatic process is catalyzed by JBP1 and JBP2 
which are capable of oxidizing methylthymine to 5-hydroxymethyluracil, and the 
intermediate is then further glucosylated by an unknown glucosyltransferase67,68 (Figure 
3). The J-binding-proteins belong to Fe(II) and 2-oxoglutarate dependent dioxygenases. 
In T. brucei, most of base J resides in silent copies of variant surface glycoproteins that 
help parasites evade host immune defense69. When computational screening of JBP 
homologues were used to predict nucleic acid modifying dioxygenases, TET family 
proteins were identified in eukaryotic cells and bacteriophages (Figure 3). Ten-eleven 
translocations are present in all metazoans but not in Caenorhabditis elegans because of a 
loss of methylation function70. On the basis of the chemical similarity between thymine 
and 5mC and the protein structure of TET, it is possible that TET proteins may oxidize 
5mC in mammalian genome.  
        All three TET proteins contain a Cys-rich domain and a carboxy-terminal catalytic 
domain that forms a double-stranded β helix (DSBH). Evolutionary studies indicate that 
the ancestor TET gene triplicated to TET1, TET2 and TET371 (Figure 5).  Furthermore, 
TET2 underwent chromosomal inversion, which resulted in the detachment of CXXC 
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domain, thereby encoding a separate gene called IDAX72. Many chromatin-binding 
proteins contain CXXC domains. The CXXC domain of IDAX preferentially binds to 
unmethylated CpG in CGIs. Strangely, TET1 CXXC domain does not bind DNA 
regardless of whether CpG is methylated or not73. On the other hand, TET3 CXXC 
domain binds to unmethylated cytosine even if the resulting nucleotide is not a guanine 
(supported by X-ray crystallography)74. Ten-eleven translocation 2 no longer has a 
CXXC domain, but instead IDAX (Figure 5). The loss of IDAX in ES cells prevents 
TET2 from being degraded in a caspase-dependent destruction mechanism during ES 
cells differentiation while the depletion of TET2 in human myeloid cell line upregulates 
TET2 and 5hmC levels. If CXXC domain of IDAX was mutated, IDAX lost the control 
of TET2 and 5hmC suggesting IDAX recruits TET2 to chromatin and TET2 binds to 
DNA through a Cys-rich domain72 (Table 1.2).  
        The C-terminal of TET2 catalytic domain is composed of a Cys-rich domain and 
DSBH domain75. The crystallized TET2 catalytic domain made it possible to uncover a 
detailed inspection of TET2 DSBH bound to methylated DNA. According to the crystal 
structure of TET2, two Zinc fingers stick Cys-rich and DSBH domains together to form a 
catalytic domain. The Cys-rich domain stabilizes DNA substrate with proximity to DSBH. 
5mC stays in the catalytic cavity in which a methyl group is pointed to Fe(II) for further 
oxidation76. The structural features of TET2 catalytic domain helps to better understand 
the mechanisms of TET-mediated DNA interaction and oxidation.  
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1.3 TET2 GENE IN HEMATOPOIESIS AND HEMATOLOGICAL DISORDERS 
        All the DNMTs contribute to hematopoiesis16. The deletion of Dnmt1 in 
hematopoietic stem cells (HSC) and progenitor cells (HPC) leads to defects in 
hematopoiesis at early stages, characterized by an insufficient myeloid cell population 
and a decreased myeloid progenitor pool77,78. The loss of Dnmt3a and/or Dnmt3b in 
mouse HSC shows a deficiency in HSCs self-renewal, with no lineage commitment of 
HSC shift. However, serial transplantation studies have shown that Dnmt3a is required to 
maintain HSC differentiation potential79,80. In addition, exome sequencing of patients 
with acute monocytic leukemia (AML-M5) indicate that DNMT3A mutations occur in 
20.5% of cases81 (Table 1.1). All of these studies demonstrate that DNMT3 are critical 
for maintaining normal hematopoiesis. 
        In addition to identified biological roles in epigenetic reprogramming, stem cell self-
renewal and embryonic development, several studies have reported the genetic alterations 
of TET2 in myeloid malignancies, including in myelodysplastic syndrome (MDS), 
myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML) and chronic 
myelomonocytic leukemia (CMML), while TET1 and TET3 are rarely mutated in 
hematological malignancies82. A large number of single/double -copy defects, nonsense 
and frameshift mutations of TET2 throughout the gene are commonly found in clinical 
patients83 (Figure 7 & 8). The above high genetic alteration frequency of loss-of-function 
mutations indicates a critical role for TET2 in the cause and/or progression of leukemia. 
And if it is true, at least biological functions of TET2 could be determined by genetic 
tools. Previously, Xu and other groups showed that Tet2, a potential tumor suppressor 
gene, has multiple biological effects on the development of myeloid malignancies84-87. 
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Although the targeting strategies were different, all of the Tet2-/- mice developed similar 
phenotypes including an elevated hematopoietic progenitor cell population, and HPC 
differentiation skewed toward myelomonocytic lineage.   
        To fully unearth and characterize the nature of Tet2 in myeloid malignancies, four 
research groups generated Tet2 knockout murine models by different strategies. For 
example, Li et al (2011) inserted nLacZ/nGFP instead of partial exon 3 of Tet2 gene 
since exon 3 is the first and largest coding exon in Tet2 and is also highly mutated in 
myeloid malignancies84. Through a specific interbreed crossing, a global knockout mouse 
model (Tet2-/-) was obtained (Figure 10). On the other hand, Moran-Crusio and 
colleagues (2011) generated a conditional knockout mouse model in hematopoietic 
compartment (vav-cre; Tetf/f)87. However, the other two groups’ disruption approaches 
were slightly different. Quivoron and colleagues (2011) generated two models, including 
a gene-trap targeting intron 9 (Tet2LacZ/LacZ) and a conditional knockout targeting exon 11 
(Mx1-cre; Tet2Lox/Lox)86. Both of these two models lost the DSBH domain, which 
eliminated dioxygenase activity in vivo.  In addition, Ko and colleagues (2011) deleted 
Tet2 exon 8-10 globally to fully remove enzymatic activity85. Together, these global or 
conditional Tet2 knockout murine models were viable and fertile and their progeny was 
in accordance with Mendelian ratio.  
        Accordingly, detailed phenotypic analyses were performed on these knockout mice. 
We have examined hematologic parameters of WT, Tet2+/- and Tet2-/- as early as 2 to 5 
months of age84. Notably, increased WBC counts and abnormal numbers of monocytes 
and neutrophils were observed in Tet2-/- peripheral blood. Besides the appearance of 
significant hepatosplenomegaly in most of the studies, we also found pale footpads in 
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Tet2-/- that may indicate anemia and this was consistent with the decrease in erythrocytes 
and platelets counts in Tet2-/-84, suggesting a possible occurrence of monocytosis and/or 
neutrophilia in Tet2-/- mice. In addition to these mentioned findings in Tet2-/- mice, other 
changes include increased bone marrow (BM) cellularity, splenomegaly and 
hepatomegaly, as well as increased numbers of colony forming unit granulocyte, 
monocyte (CFU-GM) in BM and spleen. A resulting diagnosis of these Tet2-/- mice is 
CMML. 
        The Tet2+/- and Tet2-/- mice died from 3 to 18 month as a result of spontaneous 
lethal hematological malignancies. Compared with age-matched WT mice, postmortem 
examination of Tet2-/- mice show remarkable splenomegaly and hepatomegaly, which are 
8-15 times and 2-5 times larger, respectively (Figure 10). Histologic studies reveal 
massive erythroid and/or myeloid infiltration in spleen and liver. Histopathology and 
cytospin studies identify specific cell types as myeloblasts, monocytes/macrophages and 
neutrophils84.  
        Flow cytometric analyses of BM and spleen cell from Tet2-/- mice is consistent with 
the results from the histologic analyses. Located in the infiltrated BM and spleen are 
large numbers of erythroblasts at different stages and various myeloid cell populations. 
Also, a large peritoneal mass and a few white nodules in the liver are observed, which 
contains Gr-1+CD11b+ cells, suggesting the existence of myeloid sarcoma84.  
        To determine whether Tet2 alterations contribute to HSC compartment, previous 
studies have used a range of cells. These included analyzing BM from 6-7 weeks old 
Tet2-/- mice, with the emphasis on lineage-negative (Lin-), ScaI-positive (Sca+), c-kit –
positive (c-kit+) (LSK) and LK cell populations. But even though results showed 
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increased numbers of LSK cells, no obvious myeloid malignancies were observed. 
Single-cell clonogenic assays were also performed to determine the effect of Tet2 
alterations on proliferation and differentiation of LSK cells. Here, the results showed that 
Tet2-/- LSK exhibited higher cloning efficiency than Tet2+/- and WT LSK cells along with 
CFU-GM in the colonies84. Taken together, it is reasonable to believe that the deletion of 
Tet2 stimulated the differentiation and proliferation of HSC/HPC and facilitated the 
development of myeloid malignancies. 
        Genome-wide whole exome sequencing from different groups have revealed that 
TET2 is one of the most frequently mutated epigenetic regulators in CMML (~50%)88-90, 
AML (~20%)83,91-93 and MDS (~20%)94-96 (Table 1.1). In many patients, deletion of 
TET2 on one allele at 4q24 region occurs with mutations of TET2 on a second allele94 
suggesting that haploinsufficiency of TET2 may lead to genome instability through DNA 
damage/repair pathways. More than 700 TET2 mutations have been identified in about 
2000 leukemic patients97. These harmful mutations impair the enzymatic activity of 
TET2, which ultimately result in aberrant DNA methylation profiling and decreased 
5hmC levels. The majority of TET2 missense mutations are clustered in two highly 
conserved regions (AA 1104-1478 and 1845-2002) that are considered as the catalytic 
domain of TET2 protein76. The mutations within these regions may influence protein-
DNA association, protein-protein interaction or post-translational modifications. The 
TET2 mutations have also been found in lymphoma including angioimmunoblastic T-cell 
lymphomas (~76%)98 and peripheral T-cell lymphoma not otherwise specified (~38%) 
along with Ras homolog gene family, member A (RHOA) mutations99,100.   
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        Analyses of clonal architecture and mutation frequency of MDS and CMML 
indicate that TET2 mutations occur at an early stage of cell differentiation, which leads to 
clonal expansion of leukemic stem cells101,102. However, the loss of Tet2 itself in mouse 
models is not able to initiate hematological disorders. In addition, most of TET2 alone 
mutations have been observed in older individuals with clonal hematopoiesis but without 
hematological malignancies103. Therefore, it is possible to propose that there should be 
more gene mutations that serve as “driver mutations” which occur during hematological 
malignancies initiation and/or progression. Through meta-analysis of mutational sites of 
hematological malignant patients, TET2 mutations co-exist with other gene mutations 
such as serine/arginine-rich splicing factor 2 (SRSF2), enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2) and additional sex combs like transcriptional 
regulator 1 (ASXL1) in MDS and CMML102,104,105 (Figure 9). The SRSF2 belongs to 
splicing factors that recognize 3’ splice-site and mediate ATP-dependent interactions 
between U1/U2 snRNPs and pre-mRNA. Like TET2, SRSF2 is frequently mutated in 
myeloid cancers. EZH2 is an H3K27me3 reader and it is the key component of polycomb 
repressive complex 2 (PRC2) while ASXL1 differentially recruits methylated H3 to 
promoters and it also mediates deubiquitination of H2AK119ub1104,106,107. In AITL 
patients, TET2 mutations accompany a recurrent mutation in RHOA (G17V) which is a 
small GTPase that regulates cell morphology and migration99. The DNMT3A mutations 
also co-exist with TET2 mutations in T-cell lymphomas99. Therefore, TET2 mutations 
happen in the early stages of hematopoietic stem/progenitor cells, but the mutation alone 
does not lead to malignant transformations. Additional gene mutations must occur, along 
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with TET2 mutations for oncogenesis to take place, as in the case of various types of 
hematological malignancies (Figure 11).  
        In addition to the hematological system, TET genes mutations also exist in solid 
tumors at quite low frequencies, according to The Cancer Genome Atlas (TCGA) 
database. For example, all TET genes mutations are found in colorectal cancer, clear-cell 
renal cell carcinoma and metastatic castration-resistant prostate cancer108-110. It is still 
unknown if TET mutations contribute to initiation/progression in these solid cancers. 
Additional studies will help to clarify the “driver mutations” in TET mutant background 
which trigger cell proliferation and survival during oncogenesis. Crossing TET knockout 
mice with current cancer-specific mouse models may help increase our understanding of 
TET functions.  
1.4  TETS AND 5-HYDROXYMETHYLCYTOSINE IN NEUROGENESIS AND 
NEURODEVELOPMENT 
        Neurogenesis produces various types of functional neural cells from neural stem 
cells (NSC). Neurogenesis occurs not only at the embryonic stage but also adult stage 
throughout the life span of the individual. Such could be considered as an essential neural 
activity/mechanism for regulating learning and memory111.  
        Embryonic neurogenesis in mice usually starts from embryonic day 8 (E8) to E14112. 
During E8-E10, neuroepithelial cells undergo transformation in the ventricular zone (VZ) 
and subventricular zone (SVZ), thereby allowing the cells to acquire astroglial 
properties113. These radial glial cells (RGs) have “stem” features, which trigger the 
generation of nascent neurons or intermediate neuron progenitor cells. When RGs initiate 
symmetrical mitosis, neurons are generated. However, if RGs go through asymmetrical 
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mitosis, other “stem” cells are produced114. Newly synthesized neurons and glial cells 
then migrate to the cortex during embryonic development to thicken the neocortex and 
build up complicated neural networks111. At the end of embryonic development, RGs 
detach from the ventricular zones, and move to the cortical plate and transform into 
astrocytes. Some RGs quietly remain in the SVZ and are responsible for adult 
neurogenesis113. 
        Adult neurogenesis occurs in two germinal zones of the brain: the subgranular zone 
(SGZ) in dentate gyrus and subventricular zone (SVZ) in lateral ventricles (Figure 12). 
Adult neurogenesis is regulated by many cellular activities including neural stem cell 
(NSC)/neural progenitor cell (NPC) proliferation and differentiation, fate determination, 
maturation and localization of newborn neurons115,116. And because neurogenesis occurs 
largely in these two regions, it is reasonable to postulate that neurogenesis may play a 
major role in regulating learning and memory. In SGZ, two types of NSC have been 
identified, type I and type II cells. Type I cells are radial glia-like cells, which maintain 
self-renewal and may differentiate to type II cells, even astrocytes. As well, the 
morphology and cellular markers of type I and type II cells are slightly different. Other 
than the common Nestin marker, type I cells are glial fibrillary acidic protein positive 
(GFAP+) while type II cells are GFAP-. Two cell types constitute the NSC/NPC in SVZ: 
type B cells are self-renewal radial glia-like cells that are able to differentiate to type C 
cells, and these transient amplifying cells can also transform into neuroblasts at a later 
development period115. Neurogenesis generates various types of neural cells with the 
same genome but with distinct properties, suggesting a role for epigenetic regulation in 
neurogenesis (Figure 13). Significant DNA methylation occurs in neurons and astrocytes. 
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Consider GFAP which is a cellular marker for astrocytes. The promoter region of GFAP 
is initially hypermethylated, which blocks the differentiation of astrocytes. However, at 
specific stages during development, the GFAP promoter becomes hypomethylated and 
then initiates the differentiation of astrocytes. Two additional critical neural factors, 
brain-derived neurotrophic factor (BDNF) and fibroblast growth factor (FGF), are 
regulated by Tet1 protein in terms of the demethylation of BDNF and FGF promoters117. 
        Studies that have mapped genome-wide 5hmC, have shown that 5hmC distributes 
temporally and spatially during neurodevelopment61,118,119. For example, studies have 
shown an age-dependent abundance and distribution of 5hmC in the cerebellum and 
hippocampus. Interestingly, 5hmC acquisition in these regions is different than what 
would be expected. There is no strong correlation between 5hmC acquisition and 5mC 
loss in many important neurodevelopment-related genes, therefore one could argue that 
5hmC role in gene regulation may be via a mechanism other than by transient oxidation 
in the brain118. To better understand the role of 5hmC in the brain, more than 6000 
differentially hydroxymethylated regions (DhMRs) at different ages have been identified. 
These DhMRs were only found in adult brain, from 6-week-old brain, but not in postnatal 
day 7 (P7) cerebellum, indicating long-term modification of 5hmC in the brain118,119. 
Although the correlation of 5hmC abundance and gene transcription is still unclear, the 
enrichment of 5hmC and loss of 5mC at gene bodies coincide with gene transcription 
activation119. In fact, 5hmC regulation of neurogenesis was reported in 2011. Tet1 
overexpression in the dentate gyrus (DG) significantly downregulated the methylation 
levels of Bdnf and Fgf1b, highlighting the role of 5hmC in neurogenesis117. Several types 
of neurodevelopment and neurodegenerative disorders have been found closely 
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associated with 5hmC, such as Rett syndrome, Autism spectrum disorder and 
Alzheimer’s disease120. 
        Because of the extensive roles of 5hmC and TETs, several studies have explored 
TET proteins functions in neurogenesis117,121. There is evidence that Tet1-/- mice exhibits 
robust loss (~45%) of NSCs in the SGZ compared with WT mice and neurospheres from 
Tet1-/- show growth defects. Microarray studies have shown that many genes (Galanin, 
Ng2 and Ngb) that are down-regulated during NSC proliferation121. In addition, Tet1-/- 
mice show increased hippocampal long-term repression and memory defects121. 
Moreover, in Xenopus, Tet3 has been found to regulate early eye development and 
neurodevelopment transcriptionally. Deletion of Tet3 decreases neuronal genes in the 
eyes74. The role of Tet2 in neurogenesis is still unknown. 
        My dissertation begins with a review of the molecular basis of DNA methylation 
and demethylation with a particular focus on newly identified 5hmC and TET family 
proteins, along with their contribution to the pathogenesis of hematological and 
neurological disorders. In chapter 2, I discuss the proposed work on uncovering the role 
of Tet2 in hematological malignancies. Section 2.3 introduces the methods and 
approaches being used in this chapter. I then describe the results and discussions I have 
achieved to date in Section 2.4. Later, in Section 2.5, I draw conclusions about what I 
have observed. Given the roles of 5hmC and Tet2 in the nervous system, I discuss 
specific findings of Tet2 in adult neurogenesis in chapter 3. In Section 3.3, I describe the 
materials and methods being used in this chapter. Section 3.4 presents the results 
including Tet2 regulation in NPC proliferation and differentiation. Specific conclusions 
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are drew in Section 3.5. Finally, chapter 5 summarizes all the observations of the study 
presented in chapter 2 and 3, as well as discusses directions for future research. 
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Figure 1 DNA methylation and demethylation pathways.  
(A) DNMT1 adds methyl group to hemimethylated DNA. DNMT3a/b add methyl group 
to non-methylated DNA. (B) Passive demethylation occurs through the absence of 
DNMTs. TETs mediate active DNA demethylation through hydroxylation of 5mC to 
5hmC, 5fC and 5caC, which can be recognized and removed by base excision repair. (C) 
The molecules involved in DNA methylation and demethylation. 
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Figure 3 TETs are the homolog of JBPs. 
(A) The biogenesis of base J. JBP1/2 oxidize thymidine to produce 5hmU, which can be 
further catalyzed to base J by unknown glucosyltransferases. (B) The multiple alignments 
of JBP1, JBP2, TET1, TET2 and TET3 are performed using Clustal Omega. These five 
proteins are highly conserved in their oxygenase regions.  
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Figure 4 Quantification of x in Purkinje cells and granule cells38. 
(A) Nucleoside monophosphates separated from genomic DNA in Purkinje and granule 
cells. (B) Reference map. 
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Figure 5 The protein structures of TET family. 
TETs have a DNA-binding CXXC domain at N-terminal and Cys-rich domain, DSBH 
domain located at C-terminal. An ancestral TET gene triplicated into three TET family 
members. Chromosome inversion occurred and separated TET2 from its CXXC domain, 
which generated IDAX.  
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Figure 6 Assays for mapping 5mC and 5hmC at single-base resolution. 
Traditional bisulfite sequencing separates 5mC from regular cytosine. TET-assisted 
bisulfite sequencing separates 5hmC from 5mC.  
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Figure 8 Histogram of TET2 mutations. 
Data collected from Catalogue of somatic mutations in cancer database. 
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Table 1.2  Identified TET2 interactor123. Several protein complexes, microRNA and 
small molecule have been shown to interact with TET2.  
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Figure 10 Tet2-/- mice develop lethal myeloid malignancies84. 
(A) Targeting strategy of Tet2 knockout mouse model. (B) Appearance of Tet2-/- mice 
with pale footpads, splenomegaly and hepatomegaly.  
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Figure 11 TET2 background mutations cause various hematological malignancies. 
TET2 mutations may occur in hematopoietic stem/progenitor cells with aging suggesting 
that additional genetic events lead to the initiation/progression of the diseases. 
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Figure 12 Adult neurogenesis111. 
In subventricular zone, B-cells (Quiescent RGs) are activated and produce C-cells 
(transient amplifying cells). C-cells transform to neuroblasts and migrate though rostral 
migratory stream to olfactory bulb as interneurons. In the dentate gyrus, type I 
progenitors give rise to type II progenitors, which migrate to granule cell layers and 
transform to neuroblasts. The neuroblasts then become immature neurons and merge into 
neural circuit through synaptic integration.  
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Figure 13 Transcriptional epigenetic regulators in adult neurogenesis. 
Green columns highlight the positive regulators and red columns indicate the negative 
regulators. The left columns are the regulators that impair NSC differentiation and 
neurogenesis. The right columns are the regulators that promote NSC differentiation and 
aberrant neurogenesis. This figure was modified from (Yao et al. 2014)111. 
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CHAPTER  
TET2 PROTECTS GENOMIC STABILITY THROUGH INTERACTING WITH MSH6 
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2.1 ABSTRACT 
        Ten-eleven translocation 2 is a member of dioxygenases that catalyze the multi-step 
5mC oxidation. Loss-of-function TET2 mutations are frequently associated with 
hematological malignancies; however, the underlying mechanism remains unknown. 
Here, I show that Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies. 
The mice with T-cell lymphoma/leukemia are characterized with enlargement of spleen, 
liver and thymus. The normal architecture of these organs are disrupted by abnormal 
lymphoid with cells aberrantly expressing CD4 and CD8. Mice with B-cell 
lymphoma/leukemia display enlarged lymph nodes and atypical lymphoid infiltrates are 
observed in the small intestines. Cells with B-cell lineage are altered in different tissues, 
particularly, B220+/low IgM/low CD43/CD19+ with high forward scatter. To obtain a 
more detailed view of the role of Tet2 in hematopoiesis, sublethally irradiated F1 mice 
were transferred with Tet2-/- T-cell and B-cell tumor cells. Both T-cell and B-cell 
malignancies were transplantable, suggesting the malignant and neoplastic nature of the 
infiltrating T- or B- lymphocytes in Tet2-/- mice. To explore genome-wide genetic 
alterations and multiple lineage involvement in Tet2-/- mice, additional exome sequencing 
of Tet2-/- tumors were performed, which revealed acquisition of numerous mutations, 
including genes frequently mutated in human hematological malignancies such as 
Neurogenic locus notch homolog protein 1 (NOTCH1) and fms-related tyrosine kinase 3 
(FLT3). The mutation frequency in Tet2-/- tumors is significantly greater at loci 
containing Tet2-dependent active demethylation. To investigate the underlying 
mechanism by which Tet2 loss may result in genomic instability, I found that TET2 
associates with MutS homolog 6 (MSH6), a key component of DNA mismatch repair 
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(MMR) using both Tet2-tag knock-in ES clones and human TET2 overexpressing cell 
line. The association between TET2 and MSH6 was substantiated by immunostaining. 
The latter study showed that these two proteins bind closely to each other at S-phase. To 
examine if TET2 loss impairs DNA mismatch repair, I depleted TET2 in HeLa cells. 
TET2-deficient cells displayed elevated spontaneous mutational frequencies and 
increased microsatellite instability, characteristic of MMR-deficient cells. Consistently, 
myelodysplastic syndrome patients with TET2 mutations exhibit significantly higher 
mutational events than patients without TET2 mutations. Together, these results suggest 
that TET2 protects genomic stability through interacting with MSH6, unveiling a novel 
means by which TET2 loss leads to diverse hematological malignancies. 
 
2.2 INTRODUCTION 
        Ten-eleven translocation (TET) family of methylcytosine dioxygenases (Tet1/2/3) 
catalyze the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 
which could be further oxidized to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), 
resulting in active DNA demethylation39. The dynamic methylation/demethylation cycle 
has been shown to occur at a large number of genomic loci across the genome124. Several 
studies suggest that 5hmC may also have DNA demethylation-independent functions and 
serve as stable epigenetic marks that recruit specific readers, DNA repair proteins and 
transcription factors, with limited overlap between these TET proteins119,125. TET2 
inactivation through mutations is a common event in myeloid and lymphoid malignancies, 
and has been detected also in solid tumors123. Several TET2 binding proteins have been 
identified, including O-linked N-acetylglucosamine transferase (OGT), inhibition of the 
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Dvl and Axin complex (IDAX) and early B-cell factor 1 (EBF1)72,126,127 (Table 1.2). 
Identification of critical novel partners of TET2 and unveiling functional significance of 
these interactions may provide valuable insights into the mechanism underlying the 
critical roles of TET2 in tumorigenesis of many cancers.  
        To fully unearth and characterize the nature of Tet2 in myeloid malignancies, four 
research groups generated Tet2 knockout murine models by different strategies. For 
example, Li et al (2011) inserted nLacZ/nGFP instead of partial exon 3 of Tet2 gene 
since exon 3 is the first and largest coding exon in Tet2 and is also highly mutated in 
myeloid malignancies84. Through a specific interbreed crossing, a global knockout mouse 
model (Tet2-/-) was obtained. We, and others examined hematologic parameters of WT, 
Tet2+/- and Tet2-/- as early as 2 to 5 months of age. Notably, increased WBC counts and 
abnormal numbers of monocytes and neutrophils were observed in Tet2-/- peripheral 
blood. Besides the appearance of significant hepatosplenomegaly in most of the studies, 
we also found pale footpads in Tet2-/- that may indicate anemia and this was consistent 
with the decrease in erythrocytes and platelets counts in Tet2-/-84, suggesting a possible 
occurrence of monocytosis and/or neutrophilia in Tet2-/- mice. In addition to these 
mentioned findings in Tet2-/- mice, other changes include increased bone marrow (BM) 
cellularity, splenomegaly and hepatomegaly, as well as increased numbers of colony 
forming unit granulocyte, monocyte (CFU-GM) in BM and spleen. A resulting phenotype 
of these Tet2-/- mice is potentially CMML. Histologic studies reveal massive erythroid 
and/or myeloid infiltration in spleen and liver. Histopathology and cytospin studies 
identify specific cell types as myeloblasts, monocytes/macrophages and neutrophils84. 
Flow cytometric analyses of BM and spleen cells from Tet2-/- mice are consistent with 
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the results from histologic analyses. Moreover, a large peritoneal mass and a few white 
nodules with Gr-1+CD11b+ cells were observed in the liver, suggesting the existence of 
myeloid sarcoma84. Taken together, it is reasonable to believe that the deletion of Tet2 
stimulated the differentiation and proliferation of HSC/HPC and facilitated the 
development of myeloid malignancies. 
        Here, my consideration is to uncover the mechanisms of Tet2 and to discover TET2 
interactors to better understand Tet2 loss induced tumorigenesis. Specifically, I proposed 
to: 1) characterize hematological malignancies in Tet2-/- mice; 2) use whole genome 
analyzing tools to examine Tet2-/- genomic landscape; 3) seek TET2 interactors that 
facilitate leukemogenesis; and 4) identify Tet2 regulatory network. Tet2-/- mice develop 
spontaneous myeloid, T- and B-cell malignancies. Both T-cell and B-cell malignancies 
were transplantable, suggesting the malignant and neoplastic nature of the infiltrating T- 
or B- lymphocytes in Tet2-/- mice. To explore genome-wide genetic alterations and 
multiple lineage involvement in Tet2-/- mice, additional exome sequencing of Tet2-/- 
tumors were performed, which revealed acquisition of numerous mutations, including 
genes frequently mutated in human hematological malignancies such as Neurogenic locus 
notch homolog protein 1 (NOTCH1) and fms-related tyrosine kinase 3 (FLT3). The 
mutation frequency in Tet2-/- tumors were significantly greater at loci containing Tet2-
dependent active demethylation. To investigate the underlying mechanism by which Tet2 
loss may result in genomic instability, I found that TET2 associates with MutS homolog 
6 (MSH6), a key component of DNA mismatch repair (MMR) using both Tet2-tag 
knock-in ES clones and human TET2 overexpressing cell line. To examine if TET2 loss 
impairs DNA mismatch repair, I depleted TET2 in HeLa cells. TET2-deficient cells 
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displayed elevated spontaneous mutational frequencies and increased microsatellite 
instability, characteristics of MMR-deficient cells. Consistently, myelodysplastic 
syndrome patients with TET2 mutations have significantly higher mutational events than 
patients without TET2 mutations. I therefore proposed that TET2 protects genomic 
stability through interacting with MSH6, unveiling a novel means by which TET2 loss 
leads to diverse hematological malignancies. 
         
2.3 MATERIALS AND METHODS 
2.3.1 Analyses of mice 
        Peripheral blood (PB) was collected by retro-orbital bleeding of mice and was 
smeared for May-Grunwald-Giemsa staining, and/or subjected to an automated blood 
count (Hemavet System 950FS). Morphological analysis and cell differential of BM and 
spleen samples were performed via cytospins (5x105 cells/sample) followed by May-
Grunwald-Giemsa staining. For histopathology analyses, femurs were fixed in 
formaldehyde, decalcified, and paraffin embedded. 
        Spleens, livers, lymph nodes, thymus and intestine were treated similarly except for 
the step of decalcification. Sections (4.5 μm) were stained with hematoxylin/eosin (H&E). 
Flow cytometric analysis was performed as previously described84. Total PB white blood 
cells were obtained after lysis of red blood cells. Single-cell suspensions from BM, 
spleen, liver, lymph node, thymus and PB were stained with panels of fluorochrome-
conjugated antibodies. Briefly, cells were divided into 40μl aliquots containing 2% FBS 
in PBS in 96-well plates. One microliter of antibodies was added into each well and 
incubated for 45min at 4°C. Then, the stained cells were re-suspended in 150μl 2% FBS 
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in PBS and processed for flow cytometric analysis. Dead cells were excluded by DAPI 
staining. The analyses were performed using a BD FACS CantoII or LSRII flow 
cytometer. All data were analyzed by FlowJo7.6 software. 
 
2.3.2 Tumor transfer assay 
        Tumor transfer experiments were performed to evaluate the malignant nature of the 
abnormally infiltrated T- or B-lymphocytes in the moribund/deceased Tet2-/- mice. 
Briefly, 1x106 spleen cells from primary Tet2-/- or WT mice were transplanted into sub-
lethally irradiated (600 cGy) F1 recipient mice (CD45.1/CD45.2, n=5) through tail veins. 
Recipient mice were sacrificed when they became moribund or 6 months after injection. 
Donor cell chimerism in the PB, spleen and BM were examined at the end of the 
observation period. The mice were also phenotypically analyzed to determine their 
hematological phenotype and development of T- or B-cell malignancies. None of the 
recipients receiving WT spleen cells developed pathology or gross evidence of disease 
within 6 months of transplantation. By contrast, all of the animals receiving spleen cells 
from Tet2-/- mice with T- or B-cell leukemia/lymphoma developed diseases with similar 
characteristics as those observed in their respective primary donor animals including 
elevated WBC counts, lymphocytosis, splenomegaly, enlarged lymph nodes and death. 
 
2.3.3 Generation of FLAG-V5 Tag knock-in ES cells 
        The targeting vector contained a neomycin (Neo) cassette flanked by two FRT sites, 
followed by a 0.5 kb genomic fragment upstream of the Tet2 start codon and an 
ATG/3xFlag/V5 sequence. A 2.2 kb 5′ and a 4.8 kb 3′ arm genomic fragments were 
 44
subcloned into the vector for gene targeting. All the fragments were amplified using 
KOD Xtreme™ Hot Start DNA Polymerase and ES cell genomic DNA as template.  
KOD Xtreme standard reaction: 
2X Xtreme Buffer 25 μl 
dNTPs (2mM) 10 μl 
PCR grade water 10 μl 
Primer mix  3 μl 
Template DNA  1 μl 
KOD Xtreme Polymerase  1 μl 
Total volume 50 μl 
The three-step cycling was used to amplify the targets: 94°C for 2min, 98°C for 10s, 
60°C for 30s and 68°C for 5min. Steps 2-4 were performed for 35 cycles. The targeting 
vector was linearized by EcoRI or ScaI and electroporated into 129/sv mouse ES cells 
and screened by southern blot. I then examined the levels of WT- and Tagged-Tet2 
transcripts in the Tet2:Tag ES cells by allele specific qPCR (ß-actin as internal calibrator). 
Using Tet2 primers for both WT-Tet2 and Tagged-Tet2, the expression of WT-Tet2 plus 
Tagged-Tet2 mRNA in Tet2:Tag ES cells was comparable to that in the WT ES cells. 
While, using the Tagged-Tet2 specific primers, the Tagged-Tet2 mRNA expression was 
not detected in control ES cells, suggesting the primers are Tagged-Tet2 mRNA specific. 
These data suggest that Tagged-Tet2 mRNA expression was comparable to WT-Tet2 
mRNA expression in the Tet2:Tag ES cells.  
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2.3.4 Purification of TET2-associated proteins 
        To search for binding partners of Tet2, I collected 30 plates (10cm) of Tet2:Tag ES 
cells. Briefly, cells were washed with PBS and scraped off from the plates. Then, cells 
were fully re-suspended in Buffer A (10mM HEPES pH7.6, 420nM NaCl, 1.5mM MgCl2, 
0.2nM EDTA and 25% Glycerol) in order to separate cytoplasmic protein. Next, the 
remaining suspension was incubated with Buffer C (20mM HEPES pH7.6, 420nM NaCl, 
1.5mM MgCl2, 0.2nM EDTA and 25% Glycerol) to obtain nuclear proteins. The nuclear 
extracts were incubated with 0.2 ml anti-Flag M2 beads at 4°C for at least 4h. The beads 
were washed and associated proteins were eluted twice with 200ng/μl 3xFlag peptide 
(Sigma). The eluted proteins were analyzed by 10% SDS–PAGE and gel slices were 
subjected to trypsin digestion followed by liquid chromatography and tandem mass 
spectrometry (LC-MS/MS) as described previously128. WT ES Cells were used as 
purification control. 
 
2.3.5 Constructs 
        WT TET2 was cloned into pOZ-FH-N vector. A mammalian codon optimized 
human TET2 cDNA was cloned into pcDNA3.1 vector. TET2-N (amino acid 1-942), 
TET2-M (amino acid 943-1322) and TET2-C (amino acid 1323-2002) were cloned into 
pcDNA3.1 vector. Briefly, the human TET2 fragments were amplified by PCR and the 
products were sub-cloned to pCR-Blunt II-TOPO for validating sequences.  
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Fresh PCR products 3 μl 
Salt solution 1 μl 
Water 1 μl 
pCR-Blunt II-TOPO 1 μl 
Total volume 6 μl 
The reaction was mixed gently and incubated for 5 min at room temperature. Normally, 1 
μl mixture was pipetted directly into one vial of competent cells. The vial was incubated 
on ice for 30min. Then, the vial was incubated in 42°C for 30s and on ice for 2min. Pre-
warmed S.O.C. medium was added to each vial and the vial was incubated at 37°C for 1 
hour at 225rpm. About 200μl mixture was spread on the LB agar plates with kanamycin 
for colony selection. The sequence confirmed clones were cloned into pcDNA3.1 vector 
using NheI and XhoI. Each of these vectors contained Flag-tag and nuclear localization 
signal at their N-terminal. 
 
2.3.6 RNA interference 
        shRNA sequences targeting mouse Tet2 (5′-GCTTACAGAATGGAGGGATAA-3′ 
or 5′-CGGGTTCATATTTGAATCCTT-3′) were inserted into the 
pLKO.puro.IRES.mCherry vector. Generation of lentivirus was carried out as previously 
described. shRNA sequences targeting human TET2 
(CCGGCCTTATAGTCAGACCATGAAACTCGAGTTTCATGGTCTGACTATAAGG
TTTTTTG) and human MSH6 
(CCGGGCCAGAAGAATACGAGTTGAACTCGAGTTCAACTCGTATTCTTCTGGC
TTTTTG) were cloned into pLKO.1-puro vector. 
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The tissue culture 6-well plates were treated with 0.01% poly-L-lysine for 5min at RT. 
HEK293T cells (1x106) were seeded in each well for 24h using Dulbecco's Modified 
Eagle's Medium with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin. 
When cells confluence reached 90%, transfection mixture was prepared. 3.75μl 
Lipofectamine® 3000 was diluted by 125μl Opti-MEM® Medium. Next, 500ng pLKO 
construct, 50ng pCMV-VSVG and 450ng psPAX2 were mixed with 125μl Opti-MEM® 
Medium and 5μl P3000™ Reagent. Diluted DNA was added to diluted Lipofectamine® 
3000 reagent at RT for 5min. The DNA-lipid complex was dropped to cells. The virus 
containing supernatant was collected after 24 and 48h for instant lentivirus titer test using 
Lenti-X™ GoStix™. 1x106 HeLa or NIH3T3 cells were re-suspended in 500μl lentivirus 
supernatant and transferred to 24-well plates. Polybrene (8μg/ml) was added to each well 
and the plate was centrifuged at 2000rpm for 90min at 37°C. Another 500μl complete 
medium was added to each well for 48h. The viral-infected cells were selected by 
puromycin (2μg/ml) for 72 h and then used for phenotypic and/or functional analysis.  
 
2.3.7 Real-time PCR  
        Total RNA was isolated and put on ice. The reverse transcription reaction included: 
6μl 7xgDNA wipeout buffer, 3μg RNA template and 33μl RNase-free water. The mixture 
was incubated at 42°C for 2min and placed immediately on ice. Additional 3μl 
quantiscript reverse transcriptase, 12μl 5xQuantiscript RT buffer, 3μl RT primer mix 
were added and the tube was incubated at 42°C for 15min and 95°C for 3min. First-
strand cDNA was synthesized. Real time PCR was performed using Fast SYBR Green 
master mix. Briefly, each reaction contained 10μl Fast SYBR® Green Master Mix, 2μl 
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primer mix and 2μl cDNA template. The plate was applied to Applied Biosystems 7500 
fast real-time PCR system following the program: 95°C for 20s, 95°C for 3s and 60°C for 
30s, 40 cycles. The PCR amplifications were performed in triplicate for each gene of 
interest along with parallel measurements of Gapdh or β-Actin cDNA(an internal control). 
To confirm specific amplification of the desired PCR product, melting curves were 
analyzed and PCR products were separated on a 3% agarose gel. The data was analyzed 
by 7500 Fast SDS v1.5.1.  
 
2.3.8 Western blot and co-immunoprecipitation assays 
        Cells or tissues were disrupted in either whole cell lysis buffer (50mM Tris, pH7.4, 
250mM NaCl, 5mM EDTA, 50mM NaF, 1mM Na3VO4, 1%NP40 and complete 
protease inhibitor cocktail) or nuclear extraction buffer. Briefly, cells were washed twice 
in ice-cold PBS. For each 10-cm dish, 0.5ml ice-cold cell lysis buffer was added to each 
cell culture dish, and incubated on ice for 30min. The cells were scraped off the dish and 
transferred to 1.5ml microcentrifuge tubes. The tubes were microcentrifuged for 10min at 
4°C, 13,000 x rpm. The supernatant of cell lysate was saved for immunoprecipitation or 
SDS-PAGE. 
        Supernatants or nuclear extracts were incubated with 30μl protein A/G PLUS-
Agarose (Santa Cruz Biotechnology) and incubated with rotation at 4°C for 1 hour.  
The tube was microcentrifuged for 10min at 4°C to preclear the cell lysate. Primary 
antibodies FLAG, TET2, MSH6 and so on were added into 400μl cell lysate, and 
incubated with gentle rotation overnight at 4°C. Next day, 30μl protein A/G PLUS-
Agarose was added to the cell lysate for an additional 3 hours at 4°C. Precipitates were 
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washed five times with cell lysis buffer, and the pellet was re-suspended with 30μl 
2XSDS sample buffer. The samples were heated at 95°C for 6min and centrifuged at 
13,000 x rpm for 5min. The samples were loaded on SDS-PAGE (4%-15%). The gel was 
then electro-transferred to PVDF membrane (80V, 120 min). After transfer, the 
membrane was washed with 25ml TBST for 5min and 25ml blocking buffer (5% non-fat 
milk in TBST) for 1hour at room temperature. Later, the membrane was incubated in 
10ml primary antibody dilution buffer (1:1,000) with gentle rocking overnight at 4°C. 
Next day, the membrane was washed 3 times for 5 min each with TBST. The membrane 
was incubated with horseradish peroxidase (HRP)-linked secondary antibody dilution 
buffer (1:10,000) for 1 hour at room temperature. The membrane was the washed 3 times 
for 5 min each with TBST, and ECL substrate was added onto the membrane in the dark 
and exposed to x-ray film. Proper exposure time was performed to detect signals. 
 
2.3.9 Exome sequencing and mutational confirmation 
        Initial whole-exome sequencing was carried out in order to identify candidate 
mutations in the exome of genes. The genomic DNA was captured with the NimbleGen 
mouse exome array according to the manufacturer’s protocol and 100bp paired-ended 
sequencing was performed on the Illumina HiSeq 2000. Raw sequencing reads were 
mapped to the whole mouse genome (mm10) using the PEmapper 
(http://pemapper.sourceforge.net/) with the default settings, and variant bases were 
annotated with SeqAnt (http://seqant.genetics.emory.edu/). 
        For the samples subjected to mutational detection, genomic DNA was amplified in 
selected exons by PCR, and sequenced by means of Sanger sequencing. The location and 
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types of mutations were then determined by sequencing data. 
        The exome-Seq was performed and analyzed by Thomas Wingo from Emory 
University, Georgia. 
 
2.3.10 DNA Mismatch repair assays 
        In vitro MMR assays were performed essentially as described with some 
modifications. A circular DNA substrate containing a G-T mismatch and a nick 3’ to the 
mismatch was incubated with 75 μg or 150 μg of whole cell extracts at 37°C for 15 min. 
DNA samples were digested with Nsil (repair scoring enzyme), followed by 
polyacrylamide gel electrophoresis and Southern blot analysis to identify repaired and 
unprepared molecules. 
 
2.3.11 Microsatellite instability and HPRT mutability analyses 
        The MSI and HPRT mutability analyses were performed as described previously129. 
For the detection of MSI in mouse bone marrow cells, 5 microsatellite markers (A33, 
Bat26, Bat66, D6Mit59, and D1Mit62 loci) were used. The D1Mit62 CA repeat loci were 
used as negative control as these loci are stable. For the human cell lines tested for MSI, 
independent single cell colonies were isolated in 96-well microtiter plates, and genomic 
DNA was isolated. Four microsatellite markers (BAT25, BAT26, D2S123, and D5S346) 
were used for MSI analysis. The HPRT mutation assay was conducted as described 
previously129. Cells (5x105) were seeded in triplicate 10 cm Petri dishes for 12 hr and fed 
with complete medium containing 5 μM freshly prepared 6-thioguanine (6-TG). The 
plating efficiency was determined by culturing 500 cells similarly in the absence of 6-TG. 
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After 10 days of culturing, cell colonies were visualized by staining with 0.05% crystal 
violet. The mutation frequency was determined by dividing the number of 6-TG-resistant 
colonies by the total number of cells plated after being corrected for the colony-forming 
ability. 
 
2.3.12 Confocal Microscopy and immunofluorescence analysis 
        Immunofluorescence analysis was performed as described below. Coverslips were 
treated by 0.01% polylysine for 5min at room temperature. The remaining polylysine 
solution was aspirated and the coverslips air-dried for 10min. 105 cells were seeded into 
6-well plates with coated coverslips overnight. Next day, the medium was aspirated and 
the monolayer was washed 2X with PBS. Then the cells were fixed in fresh 2.5% PFA at 
37°C for 10min. The coverslips were rinsed 2X with PBS and washed 1X with PBS in 
the dark for 10min. The cells were permeabilized and blocked with SS-PBS buffer (10% 
normal goat serum and 0.3% Triton™ X-100) at room temperature (RT) for 5min. After 
SS-PBS buffer was removed, 10μl primary antibody was added directly onto the 
coverslips for 60min. The well was rinsed 2X with PBS and 1X with SS-PBS in the dark 
for 10min. 10μl secondary antibody was added onto the coverslips directly after SS-PBS 
was removed from the well completely. The plate was left at RT in the dark for 30min. 
The coverslips were rinsed 2X with PBS, 2X with PBS+0.3% Triton™ X-100 and 2X 
with PBS. After wicking the majority of buffer from the coverslips, the coverslips were 
mounted using Prolong Gold anti-fade reagent. The coverslips were set overnight in the 
dark and used for imaging next day. Fluorescence images were obtained using Olympus 
FV1000 MPE or Leica SP8 MP. The images were analyzed by ImageJ 1.48 software. 
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2.3.13 Bisulfite-Seq and TAB-Seq 
        Genomic DNAs (500ng) from WT and Tet2-/- mice LK cells were mixed with 130μl 
CT conversion reagent. The tubes were placed in a thermal cycler under the following 
program: 98°C, 10min; 64°C, 150min; 4°C for up to 20 hours. The products were 
transferred to spin columns with 600μl binding buffer. The columns with collection tubes 
were centrifuged at 10,000xg for 30s. After washing the column twice with washing 
buffer, the columns were filled with elution buffer. The eluted DNA was ready for PCR 
or further analyses. 
        Genomic DNAs from WT and Tet2-/- mice LK cells were sheared to average 400bp. 
The β-glucosyltransferase reaction was prepared as follows: 4μg sheared gDNA, 0.4μl 
10mM UDP-Glucose, 2μl 10xβGT protection buffer, 0.5μl T4-βGT and Milli-Q water to 
20μl. The reaction was performed at 37°C for 1h. The products were then purified using a 
QIAquick PCR Purification Kit. Next, 500ng gDNA from the last step was incubated 
with TET1 protein and Tet2 oxidation reagent 1&2. The reaction was carried-out at 37°C 
for 1h. 1μl Proteinase K was added to the reaction and incubated at 50°C for 1h. The 
product was purified by Micro-Bio-Spin Columns and then with QIAquick PCR 
Purification Kit. The target sites were amplified by PfuTurbo Cx DNA polymerase 
following the manufacture’s instructions. Generally, 50μl PCR included 5μl 
10xPfuTurboCx reaction buffer, 1μl 10mM dNTP mix, 2μl 5mC control primers, 4μl 
Bisulfite treated DNA, 1μl PfuTurboCx DNA polymerase and Milli-Q water to 50μl. The 
verified PCR products were used for either individual clone sequencing or Genome-wide 
Sequencing analysis. 
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2.3.14 Statistical analysis 
        To determine differences between experimental groups, I used the Student’s t-test or 
analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison tests as 
appropriate. P values < 0.05 were considered significant. For SNV count data, chi-square 
tests were used as implemented in R (http://cran.r-project.org/). 
 
2.4 RESULTS AND DISCUSSION 
2.4.1 Tet2-/- mice develop lymphoid malignancies. 
        The TET2 gene is frequently mutated in human hematopoietic malignancies. Most 
of these homozygous and heterozygous mutations lead to truncation of TET2 protein and 
subsequently decreased TET2 enzymatic activity. Several groups generated Tet2 
knockout mouse models to determine the role of TET2 in hematopoiesis and 
hematopoietic diseases84-87. Similar phenotypes were observed from these groups that 
Tet2-/- mice developed a wide spectrum of myeloid malignancies and the loss of Tet2 was 
sufficient to promote myeloid transformation. It is still unknown if the deletion of Tet2 is 
able to cause lymphoid transformation, as previously reported, that TET2 mutations also 
exist in patients with lymphoid malignancies100. A long-term investigation was performed 
to determine if the loss of Tet2 is sufficient to cause lymphoid transformation. I 
conducted a 2-year study on a cohort of Tet2-/- and 67 wild-type (WT) mice. All the Tet2-
/- mice were born with expected Mendelian ratios, were viable, fertile with normal organ 
development, suggesting Tet1 and Tet3 may have extra roles in embryonic development. 
No expression level changes in Tet1 and Tet3 were seen in hematopoietic cells after Tet2 
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deletion, which eliminates the presumption of enzymatic compensation in TET family 
and endows a unique role for Tet2 in hematopoiesis.   
        Next, I analyzed details of the incidence, latency, and pathological features of 
hematological neoplasms that occur in Tet2-/- mice and Tet2+/+ littermates. Strikingly, all 
of the 198 Tet2-/- animals developed spontaneous lethal hematological malignancies with 
a latency ranging from 3 to 18 months, while no progressive leukocytosis was 
characterized in the hematopoietic organs of WT animals (Figure 14). 
        Analyses of these Tet2-deficient mice strengthened the finding that a majority of 
(>90%) these Tet2-/- mice developed predominantly myeloid malignancies that include 
CMML-like disease, MDS and MPN with significant hematological phenotypes of 
leukocytosis (accompanied by neutrophilia and/or monocytosis), hepatosplenomegaly 
and marked expansion of well-differentiated myeloid cells or erythroid precursors in the 
bone marrow (BM), spleen, and liver that compromised the normal architecture of these 
organs. Interestingly, Tet2 loss also affects lymphoid-lineage development. The rest of 
Tet2-/- mice developed T-cell (7 of 198, 3.5%) or B-cell (9 of 198, 4.5%) 
lymphoma/leukemia (Figure 14). With age, these mice showed lymphocytosis consisting 
of atypical lymphocytes, lymphadenopathy, hepatosplenomegaly, and/or enlarged thymus 
(in most cases of T-cell malignancies).  
        The mice with T-cell lymphoma/leukemia were characterized with lymphoid 
infiltration in BM, thymus, spleen and liver (Table 2.1). Histopathological analysis of 
moribund mice indicated complete effacement of the normal architecture of these organs 
with lymphoid elements. The morphology of atypical lymphocytes was observed (Figure 
14). They were medium sized, immature appealing with irregular nuclei and small to 
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moderate amount of cytoplasm. The spleen specimen exhibited a diffuse infiltrate within 
both red and white pulp. The predominant hepatic perivascular and sinusoidal infiltrates 
were also observed after histological examinations. Flow cytometric analysis confirmed a 
predominant proportion of T-lymphocytes expressing CD3 and aberrantly co-expressing 
CD4 and/or CD8 in BM, spleen and thymus (Figure 15).  
        Atypical lymphoid infiltrate was also identified in the small intestines with 
lymphoepithelial lesions and lymphoid nodules in Tet2-/- mice diagnosed as B-cell 
lymphoma/leukemia (Table 2.2). These atypical lymphocytes were medium sized with 
irregular nuclei, condensed chromatin and small amount of cytoplasm. Nodular lymphoid 
infiltrate disrupted the normal architecture of the spleen, especially in the white pulp. 
Requisite perivascular and sinusoidal infiltration occurred in the liver. The B-cell lineage 
was also altered in different tissues, particularly, B220+/lowIgM+/lowCD43+CD19+ with 
high forward scatter (FSC) (Figure 16).  
        To obtain a more detailed view of the role of Tet2 in hematopoiesis, I transferred 
Tet2-/- spleen cells from Tet2-/- mice with T- and B-cell malignancies to sub-lethally 
irradiated WT mice. Two weeks later, transplanted mice were analyzed. Both T- and B-
cell malignancies were transplantable, suggesting the malignant and neoplastic nature of 
the infiltrating T- or B-lymphocytes in these Tet2-/- mice (Figure 17).  
        Taken together, these results show that besides myeloid malignancies, Tet2-/- mice 
also develop lethal lymphoid malignancies involving both T- and B-cell lineages. These 
finding are consistent with the clinical observations that loss of function mutations of 
TET2 are frequently associated with T- and B-cell malignancies. The kinetics of disease 
onset suggests that additional genetic lesion events may occur along with Tet2 ablation to 
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cause distinct types of hematological malignancies, either in myeloid or lymphoid lineage. 
It is reasonable to speculate that the deletion of Tet2 may contribute to locus specific 
hypermethylation. Aberrant methylation at specific myeloid, T-cell and B-cell promoters 
should correlate with transcription alterations and later disease development.  
 
2.4.2 Acquisition of mutations in Tet2-/- tumors and increased mutational frequency 
in loci marked by Tet2-dependent 5hmC 
        To explore if the loss of Tet2 leads to genome-wide genetic alterations, I performed 
comparative genomic hybridization array (aCGH) and whole-exome sequencing using 
tumor and/or non-tumor cell genomic DNA from Tet2-/- mice with myeloid-, T- or B-cell 
malignancies. In the myeloid tumor sample, CGH analysis detected a gain of 16q (Figure 
18). Both myeloid- and T-cell malignant genomes showed sub-chromosomal copy 
number alterations. While no significant alterations were seen from B-cell malignant 
genome (Figure 18).  
        The newer and current massive parallel sequencing techniques make it feasible to 
characterize somatic mutations in cancers. The exome (coding regions) sequencing 
allows us to identify driver mutations in cancer genome. To gain new insight into Tet2 
loss induced leukemogenesis and relevant molecular basis underlying the clinical finding 
of multiple lineage involvement, I performed whole exome sequencing and subsequent 
Sanger sequencing to identify somatic mutations in Tet2-/- myeloid-, T- and B-cell tumors. 
I captured and sequenced the exomes from paired samples of Tet2 loss induced tumors. 
After normalization (remove SNVs from WT and Tet2-/- non tumor samples), I identified 
potential somatic mutations including 3,309 single-nucleotide variations (SNVs) and 211 
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small insertions or deletions (indels). I analyzed the alterations affecting protein-coding 
sequence, and 1,480 non-synonymous replacement sites and 1,829 silent sites per tumor 
type were found, which influence the integrity of open reading frame. Of the Tet2-/- 
tumors from each cell origin, I found somatic mutations in 190 genes with recurrent 
SNVs that appeared to originate in the different tumors including Notch1, Ebf1, Flt3, Nf1, 
Rhoa and Ikzf3 (Figure 19). Integration of the above data, together with literature 
searching for these genes which have been frequently found in human hematological 
malignancies, led to the validation of exome sequencing results. I amplified the 
corresponding regions from original tumor samples and applied the PCR products for 
Sanger sequencing.  
        Non-synonymous mutations of Notch1 were identified in all 3 cases of Tet2-/- T-cell 
tumors. As a critical transcription factor regulating innate and adaptive immunity, 
NOTCH1 can direct hematopoietic stem cell differentiation toward T-cells. In addition, 
NOTCH1 is frequently altered in hematopoietic and solid tumors. Intriguingly, NOTCH1 
genetic mutations may lead to either ligand-independent activation or delayed turnover of 
NOTCH1 protein, depending on the context and mutation induced conformation 
changes130.  
        In the hematological system, NOTCH1 mutations have been detected not only in 
~55% of human T-cell acute lymphoblastic leukemia (T-ALL) but also in a high fraction 
of murine precursor-T lymphoma/leukemia in which NOTCH1 is a well-characterized 
oncogene130. Previous studies have shown that the HD (heterodimerization) and PEST 
(proline-glutamic acid-serine-threonine rich) domains of NOTCH1 are mutation hotspots 
in T-ALL131. Indeed, the Notch1 mutations identified by exome sequencing of Tet2-/- T-
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cell tumors are all within these hotspots (p.Leu1668Pro, p.Arg1673Pro) and the Notch1 
mutations in these hotspots were also found in 3 additional cases of Tet2-/- T-cell tumors 
(p.Thr2346---, p.Ala1639Thr, p.His1598*) (Figure 20), providing novel insight into the 
T-cell leukemogenesis caused by the loss of Tet2. 
        Together, Tet2 loss-induced tumors are characterized by the acquisition of SNVs 
and small indel, but not large chromosomal deletions/amplifications, suggesting that the 
loss of Tet2 may create a genomic instability state in cells, where gene mutations accrue 
much more readily than normal. Indeed, hypermethylation states have been shown to be a 
potential mutagen in tumor cells.  
        Given the role of TET proteins in the oxidation process of 5mC, I next examined the 
effect of the loss of Tet2 on genome-wide 5hmC modification. I mapped the genomic 
distribution of 5hmC in WT and Tet2-/- Lin-c-Kit+ (LK) BM cells using selective chemical 
labeling and affinity enrichment procedures (Figure 21). The deletion of Tet2 leads to a 
significant decrease of 5hmC at gene bodies, which is consistent with previous 
observations in mouse ES cells with a reduced expression of Tet2. The effects of Tet2 
loss engendered a striking dependence on intermediately-expressed, but not highly-
expressed genes in LK cells (Figure 22). The majority of Tet2-dependent 5hmC 
modifications in LK cells are located within the genes. Genome-wide 5hmC profiling of 
WT and Tet2-/- LK cells identified the shared loci. 
        The shared loci represent the ones with 5mC oxidation catalyzed by other TET 
proteins, such as TET1, but not Tet2 (Tet2-independent sites). Both gain and loss of 
5hmC loci in the absence of Tet2 may represent loci with Tet2-dependent 5mC oxidation 
and might reflect distinct role(s) for Tet2 in the 5mC oxidation process. The loci with the 
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loss of 5hmC in the absence of Tet2 are the ones that are converted from 5mC to 5hmC 
by Tet2 (Tet2-dependent 5mC conversion to 5hmC), while the loci with the gain of 
5hmC more likely represent the regions with further 5mC oxidation (from 5hmC to 
5fC/5caC) mediated by Tet2 (Tet2-dependent active DNA demethylation) (Figure 23). I 
then explored the overlap between the sites with SNVs/indel in Tet2-/- tumors and the 
three different genomic loci. Using a chi-square test to examine the correlation between 
mutation sites and three different genomic loci, I observed a significantly greater 
frequency of SNVs/indel within the loci that require Tet2 for active demethylation, as 
compared to that of Tet2-independent sites and the loci that require Tet2 for the 
conversion of 5mC to 5hmC alone. Similar increases were observed with either overall 
mutations or C to T (or G to A) mutations (Figure 23 & 24). Thus the genetic loci marked 
by Tet2-mediated active demethylation are likely accessible by Tet2, which could in turn 
play a role in the maintenance of genomic stability. 
        I observed a decrease in 5hmC abundance at mutation sites as these regions close to 
CpG sites, which further indicates that Tet2 loss induced genetic mutations correlate with 
Tet2-mediated DNA demethylation. To determine the dynamics of 5hmC alterations at 
mutation sites, I used single-base resolution Bisulfite-Seq and TAB-Seq to examine the 
changes of cytosine modification between WT and Tet2-/- young mice LK cells, in which 
I assumed that these mutation sites stay in origin. From representing gene analysis 
(Akap12), I found the “C” was hypermethylated in Tet2-/- cells but no expected 5hmC 
changes were observed (Figure 25), suggesting that the C base confers an essential 
function to maintain genome integrity because 5mC is considered as a mutagen in the 
genome and the accumulation of 5mC may alter its active enzymatic deamination. 
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Although I was not able to detect 5hmC changes, I cannot exclude the dynamics of 5hmC 
because of 1) 5hmC overlapping region controlled by TETs; 2) 5hmC further oxidized to 
5fC or 5caC; 3) Technique limitations.  
 
2.4.3 TET2 interacts with MSH6 
        To investigate the mechanisms by which Tet2 loss may result in genomic instability, 
I sought the functional Tet2-binding partners. I generated knock-in ES clones in which 
tandem (Flag and V5) tags were inserted after the Tet2 start codon within exon 3 through 
homologous recombination (Figure 26). The knock-in allele allows the expression of both 
Flag-tagged Tet2 and WT Tet2 at roughly 1:1 ratio in the Tet2:Tag ES cells. 
        I characterized endogenous TET2-interacting proteins by mass spectrometry, and 
identified a list of TET2-interacting proteins including the known TET2-interacting 
protein OGT, and unknown associates MSH6 (Table 2.3). These results are intriguing as 
MSH6 is specifically involved in the DNA mismatch repair (MMR) of base-base 
mismatches and small insertion/deletion mispairs generated during DNA replication129, 
consistent with the types of genetic alterations identified in the Tet2-/- tumors. To confirm 
interaction between TET2 and MSH6, I performed co-immunoprecipitation assays using 
both Tet2:Tag ES cells and Flag-TET2 overexpressing HEK293 cells (Figure 27 & 28). 
TET2 was also captured in the MSH6 precipitates from mouse BM cells, confirming the 
endogenous TET2-MSH6 interaction in primary hematopoietic cells. To map the 
interacting regions between TET2 and MSH6, I generated a series of constructs including 
Flag-TET2 fragments and Myc-MSH6 fragments. Human TET2 gene was fragmented to 
four parts: hTET2-N (AA 1-942), hTET2-M (AA 916-1921) and hTET2-C (AA 1323-
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2002, DSBH) (Figure 29). On the basis of the secondary structure of human MSH6, the 
MSH6 gene was dissected to five fragments that are MSH6-PWWP (AA 1-200), MSH6-
MutSNter (AA 183-537), MSH6-MutSConnector (AA 525-735), MSH6-MutSCore (AA 
700-1102) and MSH6-MutSCter (AA 1075-1360). TET2-N terminal showed interaction 
with full-length MSH6. To examine if MSH6 directly interacts with TET2 protein, I also 
co-expressed GST-MSH6 and TET2-N. These two recombinant proteins were co-purified 
in vitro, suggesting the direct binding between TET2 and MSH6 in vivo and in vitro. 
Moreover, the co-localization of the two proteins was examined using HeLa cells and 
immunofluorescence staining. Consistent with previous reports129, MSH6 formed distinct 
foci in the chromatin of HeLa cells, and the localization of MSH6 and TET2 largely 
overlapped in these foci (Figure 30). These data collectively demonstrate that TET2 
interacts with MSH6 in vivo.  
 
2.4.4 TET2 loss causes a mutator phenotype in cells 
        Mismatch repair (MMR) of DNA corrects base-base and small insertion/deletion 
generated during DNA replication. Since MMR reduces the DNA replication errors, 
defective MMR increases the spontaneous mutation rate, which results in the “mutator 
phenotype”129. In mammalian cells, these mispair errors are recognized by human 
heterodimer proteins hMutSα and hMutSβ. MSH2 and MSH6 are major components of 
hMutSα and they form a heterodimer to repair the mispairs. Previous studies indicate that 
the alteration of MSH2 and MSH6 expression leads to susceptibility to certain types of 
cancer, especially hereditary non-polyposis colorectal cancer (HNPCC)132. The MMR 
defects cause the instability of high frequency of insertion/deletion in microsatellites at 
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the cellular level. Microsatellite instability (MSI) is a hallmark characteristic in hereditary 
nonpolyposis colorectal cancer (HNPCC), which is associated with mutations in the 
MMR pathway genes including MLH1, MSH2 and MSH6129. In addition to colorectal 
cancer, MSI phenomenon is also observed in certain types of leukemia such as secondary 
AML and MDS133.  
        The above TET2 and MSH6 interaction data prompted the following question. Does 
TET2 loss impair MMR and subsequently cause the mutator phenotype? To answer these 
questions, I first examined the in vitro MMR activity and MSH6 expression in the 
nuclear extract of WT and Tet2-/- total BM cells. A functional in vitro MMR assay was 
performed. Surprisingly, both WT and Tet2-/- BM cell extracts restored MMR efficiently 
(Figure 32), suggesting TET2 is not a critical factor for MMR in vitro and Tet2 loss does 
not alter the expression or function of MSH6 in vitro. 
        However, if the MSH6-TET2 interaction recruits hMutSα to chromatin, I cannot 
exclude the possibility that MSH6-TET2 interaction is required for MMR in vivo. If this 
is true, TET2 deficient cells should have impaired MMR and displayed an increased 
mutation frequency. To determine MSH6 chromatin localization, I depleted TET2 by 
shRNAs in HeLa cells (Figure 33), which is a MMR-proficient cell line. I used double 
thymidine block to synchronize control of HeLa (scramble shRNAs) and TET2KD HeLa 
cells in G1, S and G2/M phase. Then, endogenous MSH6 expression levels and 
chromatin localization were determined by immunofluorescence (Figure 31). Decreased 
MSH6 foci were observed in TET2KD HeLa cells compared to control HeLa cells 
(Figure 36), suggesting that MSH6 chromatin localization is facilitated by TET2. Around 
10% of MSH6 foci co-localized with TET2 in WT HeLa cells indicating that not all 
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TET2 recruit MSH6. Like a previous report129, decreased MSH6 foci is also seen in 
G2/M phase, but not because of altered MSH6 expression.   
        Control and TET2-depleted HeLa cells were then tested for MSI at four 
microsatellite loci as described previously129. No MSI was detected in control HeLa cells, 
whereas 9-18% sub-clones (n=11) from TET2-depleted HeLa cells showed new 
microsatellite species at these loci (Figure 38). As a positive control, MSI was also 
analyzed in MSH6-deficient DLD-1 cells, which exhibited new repeat species in 27-36% 
sub-clones. Despite a difference in the percent sub-clones showing new repeat species, 
these data indicate that like MSH6-deficient DLD-1 cells, TET2-depleted HeLa cells 
display MSI. I also examined the frequency of MSI in BM DNAs from aged WT or Tet2-
/- mice. Tet2-/- BM samples showed 43-86% novel alleles at A33, Bat26, Bat66 and 
D6Mit59 loci (Figure 37), while no novel alleles were detected at these loci in each of the 
WT BM samples, further demonstrating Tet2 loss displays MSI. 
        To further confirm that the deletion of TET2 leads to the mutator phenotype, I 
measured the spontaneous forward mutation frequency in the hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) gene in TET2KD HeLa cells, control HeLa cells 
(negative control) and DLD-1 cells (positive control). Human HPRT gene encodes HPRT 
enzyme whose activity is important for DNA synthesis. 6-thioguanine (6-TG) is a toxic 
nucleoside analog and it is used for cell selection. Cells without HPRT gene mutations 
are poisoned by 6-TG, while HPRT gene mutations help cells survive and form colonies. 
As shown in Figure 34, the mutation frequency in TET2KD HeLa cells had a 24-fold 
increase compared to control HeLa cells and is ~10-fold lower than that in hMSH6-
deficient DLD-1 cells (Figure 34). The presence of HPRT mutations was confirmed in 
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mutant clones of each cell type and most of the mutations were located at HPRT hot spots. 
This is likely due to both the efficiency of TET2 knockdown and a likely TET2-
independent mechanism for MSH6-mediated MMR. Similar results were obtained using 
control and Tet2-knock down NIH3T3 cells (Figure 35), confirming that TET2 loss 
causes a mutator phenotype.  
        Lastly, I analyzed the number and type of mutations in a cohort of human MDS 
cases. Interestingly, MDS patients with TET2 mutations harbor a significantly higher 
number of mutational events compared to patients without TET2 mutations (Figure 39). 
The association of the presence of TET2 mutations with higher mutational frequencies in 
MDS patients is consistent with the findings that Tet2 loss constitutes genetic instability. 
Collectively, these observations are consistent with the hypothesis that TET2 is likely 
involved in recruitment of MSH6 to the chromatin, and TET2 loss impairs MMR in vivo 
thereby enhancing susceptibility to malignant transformation by a multitude of genetic 
mutations. 
2.5 CONCLUSIONS 
        Studies using different Tet2 knock-out animal models have revealed that Tet2 loss 
alters the epigenetic landscape with decreased 5hmC and global hypermethylation of the 
DNA, increases HSC self-renewal and myeloid progenitor expansion with skewed 
differentiation toward monocytic lineages, leading to the pathogenesis of myeloid 
malignancies84. Here, I show that a fraction of Tet2-/- mice develop lymphoid 
malignancies of both T- and B-cell origin, demonstrating that TET2 plays an important 
role in both myeloid and lymphoid malignancies. Leukemogenesis is thought to be a 
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multi-step process in which a series of genetic mutations may be acquired in a specific 
clonal lineage. Genome analysis of Tet2-/- tumors allowed not only a better understanding 
of Tet2 loss-mediated leukemogenesis, but also the identification of candidate secondary 
gene mutations that lead to diverse disease phenotypes in Tet2-/- mice.  
        The exome sequencing identified numerous SNVs/indel in Tet2-/- tumors of each 
cell origin, indicating that TET2 loss constitutes a state of genetic instability. The 
increased susceptibility of mutational acquisition is likely further accelerated in Tet2-/- 
HSC/HPCs since TET2-loss induced intrinsic changes in these cells, with increased self-
renewal and proliferation. TET2 loss represents an obvious initiating event in the 
pathogenesis of hematological malignancies. The occurrence of secondary oncogenic 
gene mutations, presumably in an early hematopoietic progenitor, is likely capable of 
modifying the disease phenotype and/or promoting the transformation/progression of a 
specific hematological malignancy in Tet2-/- mice. This is evident by the acquisition of 
Notch1, Flt3, Nf1, Ebf1, Rhoa, Ikzf3 and other gene mutations in the Tet2-/- 
hematological malignancies, consistent with the human hematological malignancy 
induction and maintenance by gene alterations of these critical genes. Consistently, 
clinical observations also suggest an initiating role for TET2 mutations in the 
pathogenesis of hematological malignancies.  
 Analysis of the clonal architecture in CMML showed that TET2 mutations are 
often the first detected oncogenic event134. As well, the prevalence of TET2 mutations is 
higher in secondary than in de novo AMLs123. Furthermore, single-cell-derived colony 
genotyping identified TET2 mutation as one of the earliest events in the accumulation of 
genetic alterations that lead to the leukemic clone expansion. And, a recent exome 
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sequencing study on angioimmunoblastic T-cell lymphoma showed that 68% of cases 
had both TET2 and RHOA mutations, and TET2 mutations predated RHOA mutations in 
most cases as RHOA mutations were specifically identified in tumor cells, whereas TET2 
mutations were found in both tumor cells and non-tumor hematopoietic cells99. 
        The MMR maintains genome stability primarily by correcting base-base and small 
indel mispairs generated during DNA replication. In mammalian cells, these mispairs are 
recognized by MSH2-MSH6 and MSH2-MSH3 complexes, both of which are required 
for MMR135,136. Tet2-/- tumors are associated with the acquisition of SNVs and small 
indel, and a significantly more SNVs were observed in loci containing Tet2-dependent 
active DNA demethylation, where Tet2 normally binds. MSH6 is a TET2, but not TET1, 
binding partner and Tet2 loss causes a mutator phenotype--hallmark of MMR defects, as 
evidenced by increased MSI and mutational frequencies at the cellular level. The data 
strongly suggest that TET2 is required for MMR in vivo by regulating MSH6 distribution 
on the chromatin. Therefore, the loss of TET2 could promote the local mutation rate in 
these Tet2-dependent active DNA demethylation loci by losing MSH recruitment. 
However, it is also possible that besides altering gene expression, the active DNA 
demethylation process itself could protect genomic stability. Indeed, 5mC has been 
shown to be a mutagen in tumor cells137. 
        Interestingly, Li et al (2013) recently showed that H3K36me3 and SETD2 are 
required for MMR in vivo, since H3K36me3 recruits hMutS onto chromatin through 
direct interaction with MSH6. Further studies are warranted to determine if H3K36me3 
and/or SETD2 play a role in the TET2-mediated recruitment of MSH6. Of note, Tet2-
deficient cells that become MMR defective are not malignant per se, but since they 
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display a consistent increase in mutational rate, they could accumulate driver mutations 
in target genes leading to malignancies. 
        My results unveil a novel role for TET2 in the maintenance of genome integrity, 
and provide significant insight into the mechanisms by which loss-of-function TET2 
mutations causes diverse human hematological malignancies (Figure 40). These 
important findings might aid the generation of new therapeutic approaches for these 
hematological malignancies. 
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Figure 14 Tet2-/- mice develop lethal lymphoid malignancies involving both T- and 
B-cell lineages. 
(A) Kaplan-Meier survival curve of WT (n = 67) and Tet2-/- (n = 198) 
mice. (B) Pie charts show the percentage of hematological malignancies of myeloid-, Tor 
B-cell origin in Tet2-/- mice (n = 198). (C) May-Grunwald Giemsa stained PB smears 
prepared from a representative WT mouse and Tet2-/- mouse with T- or B-cell 
malignancy. 
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Figure 15 Tet2-/- mice with T-cell malignancy. 
(A) The gross morphologies of lymph nodes, spleen, liver, and thymus from a 
representative Tet2-/- mouse with T-cell malignancy. (B) Flow cytometric analysis of the 
T-cell lineage (CD4/CD8) in BM, spleen and thymus of a representative Tet2-/- mouse 
with T-cell leukemia/lymphoma and an age matched WT mouse. (C) H&E stained 
histological sections of femurs, spleen and liver from a representative Tet2-/- mouse with 
T-cell leukemia/lymphoma and an age matched WT mouse. 
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Table 2.1 Phenotypic characteristics of T-cell malignancies developed in 7 Tet2-/- 
mice. 
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Figure 16 Tet2-/- mice with B-cell malignancy. 
(A) The gross morphologies of lymph nodes, spleen and liver from a representative Tet2-
/- mouse with B-cell malignancy. (B) Flow cytometric analysis of the B-cell lineage 
(B220/IgM) in BM and spleen of representative Tet2-/- mice with B-cell 
leukemia/lymphoma and an age matched WT mouse. The numbers indicate the percent 
cells in each cell population. (C) H&E stained histological sections of femurs, spleen and 
liver from a representative Tet2-/- mouse with B-cell leukemia/lymphoma and an age 
matched WT mouse. 
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Table 2.2 Phenotypic characteristics of B-cell malignancies developed in 9 Tet2-/- 
mice. 
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Figure 17 Lymphoid malignancies in Tet2-/- mice are transplantable to secondary 
recipients. 
(A) Tumor transfer schema. Spleen cells (1x106) from a WT mouse or Tet2-/- mice with 
T- or B-cell lymphoma/leukemia were each injected into sub-lethally irradiated (600cGy) 
CD45.1+/CD45.2+ F1 recipients. (B) Kaplan-Meier survival curve of sub-lethally 
irradiated recipients (5 animals / donor) transplanted with spleen cells from a WT muse 
or Tet2-/- mice with T- or B-cell lymphoma/leukemia. (C) Flow cytometric analyses on 
the T-cell lineage (CD4/CD8) within the donor (CD45.2+) cell populations of peripheral 
blood cells from a representative recipient receiving spleen cells from a WT mouse or a 
Tet2-/- mouse with T-cell lymphoma/leukemia. Flow cytometric analyses on the B-cell 
lineage (B220/IgM) within the donor (CD45.2+) cell populations of peripheral blood 
cells from a representative recipient receiving spleen cells from a WT mouse or a Tet2-/- 
mouse with B-cell lymphoma/leukemia. Data demonstrate that the recipients receiving 
spleen cells from Tet2-/- mice with T- or B-cell lymphoma/leukemia developed diseases 
similar to their respective donor mice. 
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Figure 19 Acquisition of mutations in Tet2-/- tumors. 
Selected recurrent gene mutations in Tet2-/- tumors involving myeloid-, B- or T-cell 
lineages as identified by whole exome sequencing.   
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Figure 20 Notch1 mutations were identified from Tet2-/- mice with T-cell malignancy. 
Sanger sequence traces of 4 Tet2-/- T-cell tumors with heterozygous mutations in Notch1 
are shown in the middle panel. The mutational locations are shown as red asterisks in the 
mouse Notch1 protein schematic representation (upper panel). Notch1 gene mutations 
identified by exome-sequencing and/or Sanger sequencing in 6 Tet2-/- T-cell tumors are 
summarized in the lower panel. 
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Figure 21 5hmC distribution and enriched regions with genomic features. 
(A) Distribution of averaged 5hmC enrichment at all genes in WT and Tet2-/- LK cells. 
(B) Association of 5hmC–enriched regions with genomic features in LK cells. The 
percentage of 5hmC–enriched regions overlapping a defined genomic feature was 
compared with the percentage expected to fall in that particular region by chance based 
on the genomic coverage of that region. Values are expressed as fold change from 
expected. 
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Figure 22 Changes of 5hmC among the genes with different expression levels. 
Gene expression values (RPKM) obtained from RNA-Seq were used to divide all the 
genes into four groups: Highly expressed (top 25%), Intermediate Expressed (25-50%), 
Lowly expressed (50-75%) and Non Expressed (below 75%). Distributions of averaged 
5hmC enrichment at all genes of each group in WT and Tet2-/- LK cells are shown. 
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Figure 23 Increased mutational frequency in loci marked by Tet2-dependent 5hmC. 
Significantly greater frequencies of overall SNVs/indel (A, upper panel) or C to T (or G 
to A) mutations (A, lower panel) within the loci with Tet2-dependent active DNA 
demethylation, but not the regions with Tet2-dependent 5mC conversion to 5hmC or 
Tet2-independent 5hmC modification. Example of a genomic view showing the 
overlapping feature of Tet2-dependent active DNA demethylation, with Rccd1 mutations 
(B). 
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Figure 25 Dynamic changes of 5mC and 5hmC surrounding the mutation sites. 
Akap12 mutational signature was characterized as CCG. Pie chart depicts the results of 
bisulfite-Seq and TAB-Seq.  
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Figure 26 Generation of Flag-V5 tag knock-in ES cells. 
(A) Targeting strategy for Tet2:Tag allele ES cells. The targeting vector contained a Neo 
cassette flanked by two FRT sites, followed by a 0.5 kb genomic fragment upstream of 
the Tet2 start codon and an ATG/3xFlag/V5 sequence. A 2.2 kb 5′ and a 4.8 kb 3′ arm 
genomic fragments were sub-cloned into the vector for gene targeting. Positive ES cells 
were identified by Southern blot. Square bars indicate exons. E, EcoRI. S, ScaI. (B) 
Southern blot of ES cell DNA digested with ScaI and hybridized with a genomic 
fragment external to the 5’ arm displayed a WT band of 6.3 kb and recombinant band of 
4.0 kb (left panel), and ES cell DNA digested with EcoRI and hybridized with a probe 
external to the 3’ arm displayed a WT band of 10.0 kb and a recombinant band of 8.9 kb 
(right panel). (C) Comparable WT Tet2 and Tag-Tet2 transcripts in Tet2:Tag ES cells. 
Data reported as relative expression units to the WT Tet2 expression in WT ES cells 
using ß-actin as internal calibrator. 
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Table 2.3 Table of the most relevant proteins identified by mass spectrometry in the 
purification of TET2-associated proteins using Tet2:Tag knock-in ES cells. Spectral 
counts for each interacting protein are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
No. of Peptide Size Protein 
2110 
4 199 BRCA1 
OGT 
TET2 220 78 
2163 MSH6 
115
47 174 TOP2A 
SIN3A 
1104 MSH2 
No. of Peptide (control) 
0 
2 
9 
32 
1 
1
0 
RAD51 2 0 37 
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Figure 27 Flag-TET2 is expressed as a 240kD protein and localized in the nucleus. 
pcDNA3.1-hTET2 (TET2) or empty vector (Mock) was transfected into 293 cells using 
Lipo3000 transfection reagent. (A) Schematic map of pcDNA3.1-hTET2 construct. (B) 
Western blot was performed with cytosol and nuclear fractions using anti-Flag antibody. 
A ~240kD band was detected in the nuclear fraction of TET2-transfected 293 cells, but 
not Mock cells, which agrees with the calculated molecular mass of Flag-TET2 based on 
its primary structure. (C) Cells were stained with anti-Flag antibody followed by the 
orange-fluorescent second antibody and green-fluorescent conjugated anti-F-actin 
antibody. The cells were then stained with DAPI (blue). Merged image artificially 
expressed in pink indicating co-localization of Flag-TET2 with DAPI, but not F-actin. 
 
 
 
 
 
 
 
 
 
 
 
 
A
B C
 F
R
w
or
im
F
u
in
ce
 
 
 
 
 
 
A
B
igure 28 TE
eciprocal co
ith MSH6 in
 Flag-TET2
munopreci
lag-TET2, M
sing indicate
teraction wi
ll as previo
T2 associa
-immunopre
 HEK293T
 overexpres
pitated with
SH6, OGT
d antibodie
th OGT in b
usly reporte
tes with MS
cipitation a
 cells overex
sing (TET2)
 anti-Flag (A
 and MSH2 
s. Whole cel
oth Tet2:Ta
d. 
85
 
H6. 
nd western b
pressing Fl
 HEK293 ce
) or anti-M
in the precip
l lysate was
g ES cells a
 
lots confirm
ag-tagged T
ll nuclear ly
SH6 (B) ant
itates was v
 used as the 
nd Flag-TE
ed the inter
ET2. Non-tr
sates were 
ibodies. The
isualized by
input. TET2
T2 overexpr
action of TE
ansfected (c
 presence o
 western bl
 shows 
essing HEK
T2 
trl) 
f 
ot 
293 
 86
 
Figure 29 MSH6 co-immunoprecipitates with TET2 N-terminal. 
MSH6 failed to bind to TET2M and TET2C in HEK293 cells overexpressing each Flag-
tagged TET2 fragments. Nuclear extracts were immunoprecipitated with anti-MSH6 
antibody and probed with anti-FLAG or anti-MSH6 antibodies. 
 
 
 87
 
Figure 30 Immunostaining identified TET2 and MSH6 co-localization. 
MSH6 foci formation and MSH6-TET2 co-localization in HeLa cells. 
Immunofluorescence was performed to determine nuclear distribution of MSH6 and 
TET2. Cells were stained with anti-TET2 antibody followed by the red-fluorescent 
second antibody and anti-MSH6 flowed by green-fluorescent second antibody. The cells 
were then stained with Hoechst33342 (blue). Merged image artificially expressed in 
yellow indicating co-localization of TET2 with MSH6 in the nuclear. 
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Figure 31 TET2 and MSH6 co-localization at different cell cycle. 
HeLa cells were synchronized at G1, S and G2/M phase using double thymidine block. 
Immunofluorescence was performed to determine co-localization of MSH6 and TET2. 
Cells were stained with anti-FLAG antibody followed by the red-fluorescent second 
antibody and anti-MSH6 flowed by green-fluorescent second antibody. Merged image 
artificially expressed in yellow indicating co-localization of TET2 with MSH6 in the 
nucleus. 
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Figure 32 Tet2 is not physically involved in MMR activity in vitro. 
In vitro MMR assay using nuclear extracts isolated from WT or Tet2-/- BM cells. 
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Figure 33 Knockdown of TET2 in HeLa cells using human TET2-specific shRNA. 
Western blot and qPCR analysis showing the expression of TET2 protein and mRNA in 
HeLa cells stably transfected with a scrambled shRNA or a TET2-specific shRNAs. 
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Figure 34 Increased mutational frequency in TET2 knockdown HeLa cells. 
(A) HPRT mutability in control- and shTET2-HeLa cells. Data presented as mean ± SD. 
Fold increase in mutation frequency was calculated using the mutation frequency of 
control NIH3T3 cells as a reference, and a t test was used to estimate a p value. (B) Low 
density 6-TG survival assay indicating resistance of TET2 knockdown HeLa cells. 
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Cell line Mutation 
Frequency (x10
-7
)
Fold change of 
Mut.Freq. 
p value 
NIH/3T3  
Scramble shRNAs 9.3 1 0.027
NIH/3T3  
Tet2 shRNA1 142.9±22.5 (SD) 15
DLD-1 1370.6±66.4 (SD) 148  
 
Figure 35 Increased mutational frequency in shTet2-NIH3T3 cells. 
(A) Western blot and qPCR analysis showing the expression of Tet2 protein and mRNA 
in NIH3T3 cells stably transfected with a scrambled shRNA or a Tet2-specific shRNAs. 
(B) HPRT mutability in control- and shTet2-NIH3T3 cells. Data presented as mean ± SD. 
Fold increase in mutation frequency was calculated using the mutation frequency of 
control NIH3T3 cells as a reference, and a t test was used to estimate a p value. 
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Figure 36 MSH6 foci formation and localization in control- and shTET2- HeLa cells 
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Figure 37 Analysis of PCR product patterns of microsatellite markers in bone 
marrow cells from WT and Tet2-/- mice. 
The appearance of novel length alleles of the A33, D6Mit59 loci is indicated (asterisk) 
for each sample. The D1Mit62 CA-repeat locus was used as a negative control, as this 
locus is stable. No alterations were found at this stable locus in both WT and Tet2-/- 
samples. 
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Figure 38 Analysis of PCR product patterns of two microsatellite markers in 
control- and shTET2-HeLa cells. 
The asterisk shows the clone exhibiting new repeat species. 
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Figure 39 Mutation numbers in MDS patients with or without TET2 mutations. 
Exome sequencing data from a cohort of human MDS patients were analyzed for the 
number and type of mutations and were summarized as mean ± SD in groups with (n=5) 
or without (n=5) TET2 mutations. 
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Figure 40 Proposed model for loss of Tet2 induced hematological malignancies. 
In wild type individuals, active DNA demethylation can be initiated by TET2-mediated 1) 
left panel, TET2 catalyzes the hydroxylation of 5mC to 5hmC, followed by 
AID/APOBEC mediated conversion from 5hmC to 5hmU, which can be further 
recognized by TDG and repaired through BER pathway. 2) right panel, 5mC is 
metabolized through deamination to T to generate T:G mismatch, followed mismatch 
repair mechanism through TET2 recruited MSH2, MSH6 heterodimer complex, which 
replace T back to C during DNA replication. In Tet2-/- individuals, the loss oxidative 
enzymatic activity eliminate Tet2-mediated oxidative pathway; while 5mC can still be 
converted to T. The newly generated T:G mismatch could not be repaired by MSH2, 
MSH6 heterodimer because of the loss of Tet2. This may eventually lead to disease-
causing mutations. 
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CHAPTER 
TET2 REGULATES ADULT BRAIN NEUROGENESIS 
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3.1 ABSTRACT 
        Previous studies that have mapped genome-wide 5hmC, have shown that 5hmC 
distributes temporally and spatially during neurodevelopment61,118,119. Interestingly, 
5hmC acquisition in these regions (5mC specific) is different than what would be 
expected. There is no obvious correlation between 5hmC gain and 5mC loss in many 
important neurodevelopment-related genes, therefore one could argue that 5hmC role in 
gene regulation may be via a mechanism other than by transient oxidation in the brain118. 
In 2011, a study found Tet1 overexpression in the dentate gyrus (DG) significantly down-
regulated the methylation levels of Bdnf and Fgf1b, highlighting the role of 5hmC in 
neurogenesis117. In addition, several types of neurodevelopment and neurodegenerative 
disorders have been found closely associated with 5hmC, such as Rett syndrome, Autism 
spectrum disorder and Alzheimer’s disease. Because of the extensive roles of 5hmC and 
TETs, several studies have explored TET proteins functions in neurogenesis117,121. There 
is evidence that Tet1-/- mice exhibit robust loss (~45%) of NSCs in the SGZ compared 
with WT mice, and neurospheres from Tet1-/- show growth defects. Microarray studies 
have shown that many genes (Galanin, Ng2 and Ngb) that are involved in NSC 
proliferation are down-regulated121. In addition, Tet1-/- mice show increased hippocampal 
long-term repression and memory defects121. 
        Because DNA methylation is critical for postnatal neurodevelopment, 5hmC may 
also be involved in 5mC dynamics during aging. I first assessed the abundance of 5hmC 
in the subventricular zone of the lateral ventricles and there was a substantial overlap 
between 5hmC+ and NeuN+ cells in the granule cell layer in the dentate gyrus of the 
hippocampus, whereas I noted a significant decrease of Tet1 mRNA and increase of Tet2 
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mRNA in an age-dependent manner. Also, I observed the down-regulation of 5hmC 
abundance at both postnatal day 7 and adult age compared to WT. Furthermore, to 
explore the function of Tet2 in adult neurogenesis, BrdU incorporation assay and 
immunofluorescence staining were performed. Interestingly, Tet2 positively regulates 
neural stem/progenitor cells proliferation and differentiation. As well, luciferase reporter 
assay indicated that Tet2 regulates the methylation dynamics of NeuroD1 and Gfap 
promoter regions. Consistent with these observations, mRNA levels of NeuroD1 and 
Gfap were decreased in Tet2-deficient cells. These results suggest that Tet2 is positively 
involved in adult brain neurogenesis through epigenetic regulation. 
 
3.2 INTRODUCTION 
        Adult neurogenesis occurs in two germinal zones of the brain: the subgranular zone 
(SGZ) in dentate gyrus of the hippocampus and subventricular zone (SVZ) within the 
walls of the lateral ventricles. Adult neurogenesis can be regulated by many cellular 
activities including neural stem cells (NSC)/neural progenitor cells (NPC) proliferation 
and differentiation, fate determination, maturation and localization of newborn 
neurons115,116. Since neurogenesis exists in these two regions, it is possible to postulate 
that neurogenesis may regulate learning and memory. As well, adult neurogenesis can be 
regulated by signaling pathways and epigenetic regulators116,138.  
        Ten-eleven translocation (TET) family proteins contain two key components: Fe (II) 
and 2-oxoglutarate (2-OG) to catalyze oxidation of the methyl group of 5mC to 
hydroxymethyl, formyl and carboxyl groups, which generate 5-hydroxymethylcytosine, 
5-formylcytosine and 5-carboxylcytosine in an enzymatic activity-dependent manner39,65.  
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        Studies that have mapped genome-wide 5hmC, have shown that 5hmC distributes 
temporally and spatially during neurodevelopment61,118,119. For example, studies have 
shown an age-dependent abundance and distribution of 5hmC in the cerebellum and 
hippocampus. Interestingly, 5hmC acquisition in these regions is different than would be 
expected. There is no strong correlation between 5hmC acquisition and 5mC loss in many 
important neurodevelopment-related genes, therefore one could argue that 5hmC role in 
gene regulation may be via a mechanism other than by transient oxidation in the brain118. 
To better understand the role of 5hmC in the brain, more than 6000 differentially 
hydroxymethylated regions (DhMRs) at different ages have been identified. These 
DhMRs were only found in adult brain, from 6-week-old brain, but not in postnatal day 7 
(P7) cerebellum, indicating long-term modification of 5hmC in the brain118,119. Although 
the correlation of 5hmC abundance and gene transcription is still unclear, the enrichment 
of 5hmC and loss of 5mC at gene bodies coincide with gene transcription activation119. In 
fact, 5hmC regulation of neurogenesis was reported in 2011. Overexpression of Tet1 in 
the dentate gyrus (DG) significantly down-regulated the methylation levels of Bdnf and 
Fgf1b, highlighting the role of 5hmC in neurogenesis117. Several types of 
neurodevelopment and neurodegenerative disorders have been found closely associated 
with 5hmC, such as Rett syndrome, Autism spectrum disorder and Alzheimer’s 
disease119,120,139,140. 
        Because of the extensive roles of 5hmC and TETs, several studies have explored 
TET proteins functions in neurogenesis117,121. There is evidence that Tet1-/- mice exhibits 
robust loss (~45%) of NSCs in the SGZ compared with WT mice, and neurospheres from 
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Tet1-/- show growth defects. Microarray studies have shown that many genes (Galanin, 
Ng2 and Ngb) that are down-regulated during NSC proliferation121. 
        The TET2 gene is well-characterized in the hematological system, however, little is 
known about its biological role in the nervous system. Considering the high abundance of 
5hmC in the mouse adult brain, I tested the assumption of a critical role for Tet2 in the 
adult brain and for changes in neural processes, by proposing to examine roles and 
relationships of Tet2 in the nervous system using a Tet2 knockout mouse model.  
        To this effect, I answer the following three questions regarding to TET2 in nervous 
system: 1) Does Tet2 loss alter 5hmC level in the brain? 2) Does Tet2 regulate the 
proliferation and differentiation of NSCs? 3) What are the downstream targets of Tet2 in 
the brain? First, I used Tet2-/- mouse models to examine the expression and localization 
of Tet2 at an embryonic stage. Because of the association between 5hmC and Tet2, I also 
measured 5hmC abundance in different brain tissues in the absence of Tet2. During NSC 
proliferation, DNA methylation can remain with relatively long-lasting effects after 
several rounds of cell division138. As another form of epigenetic mechanism, DNA 
methylation indeed plays an essential role in regulating adult neurogenesis. Previous 
studies on Methyl-CpG-binding domain 1 (MBD1) and methyl CpG binding protein 2 
(MeCP2) indicated their binding methylated CpG capacity in the promoters, which 
subsequently suppressed gene expression. Mice with Mbd1-deficiency showed decreased 
neurogenesis and impaired cognition through behavior studies.  The promoter of fgf2 was 
hypomethylated, which led to decreased neuronal differentiation141. In another study, 
when Mecp2 was down-regulated, abnormal maturation and synaptogenesis of granular 
neurons were present. Also, MeCP2 may influence glia-specific gene expressions like 
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GFAP142. More recently, a DNA demethylation study of Tet1 showed that Tet1 is 
involved in neuronal active DNA demethylation and gene expression in mouse dentate 
gyrus117. And, although Tet2 has been shown to be involved in hematopoietic 
malignancies, the expression of Tet2 is relatively high in the nervous system than 
hematological system143.  
        Therefore, I used Tet2-/- mouse model to investigate whether Tet2 can regulate adult 
neurogenesis. The loss of Tet2 increased the proliferation of NSC and decreased the 
differentiation of NSC. Since DNA methylation is critical in postnatal neurodevelopment 
and seems to undergo age-dependent changes in the brain, I collected and examined the 
hippocampus and cerebellum of mice at postnatal day 7 (P7), 6 weeks and 1 year of age. 
Proliferation and differentiation of NSC/NPC and the underlying molecular mechanisms 
were examined to uncover the role of Tet2 in adult neurogenesis.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Generation of Tet2-/- mice and LacZ staining 
        Tet2: LacZ KI mice were generated as previously described84. Briefly, the start 
codon ATG was replaced by LacZ: GFP: Neo cassette. After crossing with Flipase 
and/Cre mice, Tet2: LacZ and Tet2: GFP mouse models were obtained. The female mice 
were euthanized according to The Guide and as required by IACUC protocol. Embryos 
were collected from the uterus and extra tissues were removed in PBS. Embryos were 
fixed in whole mount fixative for 40min on ice and rinsed 3 times (3X) in PBS for 15min 
each. The fixed embryos were then stained by X-gal staining solution at 37°C O/N in the 
dark, then rinsed in PBS for imaging. 
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3.3.2 Adult NPCs isolation and culture 
        Neural progenitor cells were isolated from 6-week-old male WT and Tet2-/- mice. 
Briefly, the dentate gyrus (DG) was dissected-out from coronal sections. Enzymatic 
digestion was used to dissociate the cells. Dulbecco’s Modified Eagle Medium (DEME) 
supplemented with 10% FBS, 2mM L-Glutamine and 1% P/S was added to each sample. 
The cells were filtered through 70-μm cell strainer and washed with DMEM. The cells 
were then loaded onto 50% Percoll for ultracentrifugation at 127k RPM fro 30 min at 
20°C. NPCs fraction was cultured in DMEM supplemented with 20ng/ml FGF2, 
20mg/ml EGF in a 5% CO2 cell culture incubator at 37°C.  
 
3.3.3 Proliferation and differentiation analyses of cultured adult NPCs  
        Neural progenitor cells (between passage 4 to 10) were trypsinized and placed on 
poly-L-laminin coated chamber slides. Each well contained about 50,000 cells and 
complete DMEM medium supplemented with growth factors (FGF2 and EGF). 20 hours 
after plating, the culture medium was supplemented with 5μM BrdU for an additional 8h. 
NPCs were fixed with 4% paraformaldehyde solution (PFA) for 30min at room 
temperature followed by 1M hydrochloric acid (HCl) for 30min at 37°C and then washed 
by borate buffer for 30min, for immunohistochemistry. For NPCs differentiation, NPCs 
were cultured with differentiation medium, DMEM with 5μM forskolin, 1μM retinoic 
acid and 0.5% FBS. The NPCs were cultured by differentiation medium for 4 days in a 5% 
CO2 cell incubator at 37°C for immunostaining later.  
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3.3.4 Real-time PCR 
        Total RNA was purified from WT and Tet2 KO brain tissue using RNeasy kit 
(Qiagen). The RNA was reverse transcribed to cDNA. RT-qPCR was performed in 20μl 
aliquots with 10μl Fast SYBR Green Master Mix, 200nM forward and reverse primers 
mix and 20ng cDNA. The triplicate reactions were applied to ABI 7500 Fast Real-Time 
PCR System and quantified using SDS 1.4 software. The relative quantification of Tet2 
mRNA was determined by threshold cycle value and normalized to the corresponding 
value of mouse actin. 
 
3.3.5 Confocal Microscopy and immunofluorescence analysis 
        The protocol has been described in the previous chapter. Briefly, cells were grown 
in 6-well plates on coverslips. Growth medium was aspirated and cells were fixed with 4% 
formaldehyde in PBS for 15 min at room temperature. Then, the fixative was discarded 
and the cells were rinsed with PBS 3 times. The cells were incubated by blocking buffer 
for 60min and then incubated with primary antibody overnight at 4°C. The primary 
antibody was removed and fluorochrome-conjugated secondary antibody was added to 
the specimen for 1h at room temperature in the dark. Coverslips were mounted by DPAI 
associated mount reagent and observed by fluorescence microscopy. 
 
3.3.6 Dot blot 
        Genomic DNA was isolated from NSC harvested from WT and Tet2-/- hippocampus 
and denatured by 0.2N NaOH. Samples were dotted on nitrocellulose membrane. After 
cross-linking by ultraviolet, the membrane was blocked in 10% nonfat milk and 1% 
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bovine serum albumin (BSA). The primary antibody anti-5hmC and secondary antibody 
HRP-conjugated goat anti-mouse were incubated with membrane, respectively. Signals 
were detected by ECL detection system as described in the previous chapter. 
 
3.3.7 DNA plasmids and luciferase assay 
        NeuroD1 and Gfap promoter regions were amplified by PCR from mouse brain 
cDNA. The PCR products were cloned into pGL3 and confirmed by Sanger sequencing. 
Human elongation factor 1a promoter region served as an internal control. 2x106 NPCs 
were trypsinized and mixed with plasmids, and then applied to electroporation. The cells 
were placed into proliferation medium and differentiation medium for 24h and 48h, 
respectively. The cells were then lysated and collected for luciferase assay. About 20μl 
cell lysate was mixed with 100μl Luciferase assay buffer II. F-luc activity was measured 
by SpectraMax M2E plate reader and the mixture was stopped using Glo Buffer with 
substrate. After normalization with R-luc, the transfection efficiency was calculated 
based on a commercial manual (Promega).  
 
3.3.8 Statistical analysis 
        To determine differences between experimental groups, I used the Student’s t-test or 
analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison tests as 
appropriate. P values < 0.05 were considered significant. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 TET2 is highly expressed in the central nervous system  
        Since DNA methylation is critical for postnatal neurodevelopment in an age-
dependent manner, 5hmC may also be involved in 5mC dynamics during aging. To 
address these issue, I assessed the abundance of 5hmC in anterior regions of the 
subventricular zone (SVZa), a region of high neurogenesis, and rostral migratory stream 
in olfactory bulb (RMS-OB) using 5hmC specific antibody. This procedure allowed me 
to discover the most active neurogenesis regions with 5hmC positive cells, which also 
helped to define the regions to be studied in the future. Immunohistochemistry of 5hmC 
in these regions showed no significant co-localization between 5hmC positive cells and 
NeuN positive cells in SVZa (Figure 41). However, in the granule cell layer (GCL), there 
was a substantial overlap between 5hmC+ and NeuN+ cells, suggesting 5hmC is required 
for neurodevelopment. Because TET family proteins catalyze the oxidation of 5mC to 
5hmC37, I speculated that Tets may be required for 5hmC dynamics during 
neurodevelopment. A significant decrease of Tet1 mRNA levels was seen during aging 
from P7 to 6 weeks old, in the cerebellum, whereas an increase in Tet2 mRNA levels 
occurred during aging (Figure 42). Together, the data suggest that both 5hmC and Tet2 
are required for age-dependent neurodevelopment. 
        To determine genome-wide Tet2 function and 5hmC distribution during 
neurodevelopment and aging, I used a Tet2 knockout mouse model that had been 
previously generated in Dr. Mingjiang Xu’s lab. To examine the localization of Tet2 in 
vivo, LacZ-GFP-Neo lines was mated with Flipase mice to acquire LacZ-GFP line. The 
embryos of Tet2: LacZ were collected at embryonic day 13.5 (E13.5) and stained with 
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regular β-gal (Figure 43). Despite some staining variability between embryos, the LacZ 
expression was observed in both the cerebellum and spinal cord suggesting a potential 
role for Tet2 in neural cells. 
        To further confirm the elimination of Tet2 in Tet2 knockout mouse models, I 
collected the brains of Tet2: GFP. The brain tissue was disrupted and total RNA was 
purified from it. After reverse transcription, cDNA of Tet2: GFP was applied to RT-
qPCR to examine relative Tet2 expression. Five primers were designed, which aimed at 
exon3, 4, 6 and 11 (Figure 44). Clearly, Tet2 was completely lost at ATG region exon3 
and exon4. However, there was still low abundance of the last several exons that may be 
due to the different splicing forms of Tet2. 
        Although I did not see developmental defects in Tet2-/- mice, the role of Tet2 in adult 
functioning still needs to be elucidated. Given the high abundance of 5hmC in mouse 
brain, it is reasonable to propose a regulatory function for Tet2-mediated 5mC oxidation 
in adult neurogenesis. To determine whether Tet2 deficiency affects 5hmC dynamics, I 
compared the abundance of 5hmC of WT and Tet2-/- mice cerebellum. At P7, 5hmC in 
Tet2-/- samples decreased to half of the amount of 5hmC in WT samples. In adults, 5hmC 
in Tet2-/- samples decreased to 3/4 of the amount of 5hmC in WT samples (Figure 45). 
This suggests that Tet2 is required for 5hmC dynamics in both P7 and adults.  
 
3.4.2 Hydroxylation of 5-methylcytosine affects stem cell proliferation and 
differentiation in dentate gyrus of the hippocampus 
        To explore the function of Tet2 in adult neurogenesis, I examined the expression 
pattern of 5hmC in the dentate gyrus of adult hippocampus. I isolated adult NPC from 
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dentate gyrus of WT and Tet2-/- mice. As shown in (Figure 46), all cultured adult NPCs 
showed positive Nestin and Sox, which are the markers for progenitor cells. It is feasible 
to use these cells for molecular and functional analyses because of their homogeneity. I 
then examined the proliferation of these NPCs by exposing the cells to BrdU for eight 
hours. It is obvious that Tet2-/- NPCs exhibited 1.5 fold BrdU incorporation compared to 
that in WT NPCs. 
        To determine the effect of Tet2 on NPC differentiation, both WT and Tet2-/- DG 
NPCs were exposed to differentiation medium for three days. Several independent assays 
were performed to investigate the phenotypes of WT and Tet2-/- NPCs differentiation 
(Figure 47). I first stained the differentiated cells with β-III tubulin (Tuj1) and glial 
fibrillary acidic protein (GFAP) (Figure 48). Tuj1 and GFAP are specific cell markers for 
neurons and astroglia, respectively. In addition to WT NPCs, Tet2-/- NPCs were also able 
to differentiate to neurons and astrocytes. Interestingly, Tet2-/- NPCs showed a 70% 
decrease in neuronal cell differentiation and a 50% decrease in astrocyte differentiation 
compared with WT NPCs. These data indicate Tet2 negatively regulate NPC proliferation 
but positively regulate NPC differentiation. 
 
3.4.3 TET2 regulates the expression of NeuroD and GFAP transcriptionally 
        The downstream targets of Tet2 are still unknown. To validate the 
immunocytochemical results, I tested the assumption that two neural cell markers may be 
altered by Tet2 deletion: neurogenic differentiation 1 (NeuroD1) and GFAP. NeuroD1 is 
a pan-neuronal transcriptional activator, which contributes to transcriptional regulation of 
neurogenesis. GFAP is an astrocyte specific cell marker during development. The 
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NeuroD1 and Gfap promoters were cloned upstream of luciferase reporter construct, 
allowing the detection of transcriptional features of these neural factors. Cells lysates 
were mixed with luciferase substrate and measured by luminometer. As I expected, the 
deletion of Tet2 suppressed the Luc activity at 48h post-transfection. Little luciferase 
expression was shown in Tet2-/- cell lysate. Furthermore, the relative mRNA expression 
of NeuroD and Gfap in Tet2-/- NSC were much lower than that in WT NSC (Figure 49). 
Taken together, these data suggest that Tet2 is capable of regulating NeuroD and Gfap 
expression through promoter suppression. 
 
3.5 CONCLUSIONS 
        TET family proteins have been well-studied recently, especially their enzymatic 
function in active DNA demethylation39. However, the physiological function of Tet2 in 
neural systems remains unknown. Although no significant development defects were 
observed in Tet2-/- mice from previous reports84, my data indicates a transcriptional 
regulatory role for Tet2 in adult neurogenesis. 
        To determine if the transcription levels of Tets change during postnatal development 
and aging, I measured Tet1, Tet2 and Tet3 mRNA levels at two different ages, P7 and 6 
weeks of age. I observed a remarkable decrease of Tet1 mRNA and increase of Tet2 
mRNA during aging, suggesting potential opposite functions of Tet1 and Tet2 during 
postnatal development. Indeed, I found that Tet2 was expressed in the brain and spinal 
cord from Tet2:LacZ mouse models. Immunostaining of 5hmC showed Tet2 regulates 
5hmC abundance preferentially in SGZ rather than SVZ. Finally, I found that overall, 
5hmC abundance was decreased in both Tet2-/- proliferating cells and Tet2-/- 
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differentiating cells, suggesting that the loss of Tet2 impairs the oxidation of 5mC and 
subsequently influences NPC proliferation and differentiation. I also examined 
proliferation and differentiation of WT and Tet2-/- NPCs in vitro. Loss of Tet2 leads to 
decreased neuronal differentiation and glial differentiation. I speculated these cellular 
phenotypes might be induced by the alterations of neural-related transcription factors, 
which results from the hypermethylation in their promoter regions. Notably, I found two 
genes NeuroD1 and GFAP mRNAs were reduced and their promoter activities were 
decrease in Tet2-/- cells. Therefore, it is possible that during adult neurogenesis, Tet2 
regulates the gene’s promoter region and catalyzes the oxidation of 5mC, which allows 
the transcriptional activation of the genes and balances neuronal and glial cell numbers. 
        In summary, I characterized Tet2 and 5hmC in mouse cerebellum and hippocampus 
during postnatal development and aging. Tet2 regulates 5mC oxidation at NeruoD1 and 
Gfap promoter regions during aging, pointing to a critical role for Tet2 in adult 
neurogenesis. My study has great potential to improve the understanding of Tet2-
mediated DNA demethylation in neurodevelopment and neurodegenerative disorders.   
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Figure 41 Immunostaining of 5hmC in two brain regions in mice. 
(A) 5hmC specific immunostaining in 6-week old anterior regions of subventricular zone. 
(B) 5hmC specific immunostaining in 6-week old olfactory bulb.  
 
 
  
A B
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Figure 42 Tet1, Tet2 and Tet3 expression levels in P7 and 6-week old cerebellum. 
Quantification of Tet1, Tet2 and Tet3 mRNA levels in different individuals (A&B) (n = 3, 
mean ± SEM.; *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA)   
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Figure 43 Tet2 is expressed in the nervous system. 
(A) Gene targeting strategy. Exons are filled boxes and LacZ-GFP-Neo cassette was 
introduced into Tet2 start codon region. (B) LacZ staining of Tet2:LacZ embryos 
showing Tet2 expression in the brain and neural tube. 
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Figure 44 Detection of Tet2 in WT and Tet2-/- hippocampi.  
(A) Schematic of real-time PCR primers used to detect Tet2 mRNA. (B) The sequences 
of real-time PCR primers. (C) Real-time PCR analysis of Tet2 mRNA levels in the brain.  
Actin was used for sample normalization. 
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Figure 45 Quantification of 5hmC in P7 and adult cerebellum.  
(A) Measurement of 5hmC in genomic DNA from P7 and adult cerebellum by dot blot 
using anti-5hmC antibody.  (B) 5hmC quantification of (A).  
A
B
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Figure 46 Cultured adult neural progenitor cells expressed representative cell 
markers. Nestin (cytoplasmic, red) and Sox2 (nuclear, green; DAPI in blue). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nestin Sox2 DAPI Merge 
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Figure 47 Quantification of 5hmC in proliferating and differentiating cells from WT 
and Tet2-/- adult NPCs.  
(A) NPCs were harvested from WT and Tet2-/- mice with splenomegaly. (B) Detection of 
5hmC in adult NPCs from WT and Tet2-/- mice. (C) 5hmC dynamic changes in 
proliferating cells and differentiating cells from WT and Tet2-/- adult NPCs.  
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Figure 49 The NeuroD1 and Gfap promoter regions are altered by Tet2.  
(A) The NeuroD1 and Gfap promoter regions were cloned into luciferase reporter 
constructs. (B) Luciferase reporter assay showed decreased NeuroD1 and Gfap promoter 
activities in Tet2-/- differentiating NPCs. Renilla luciferase (R-Luc) plasmid served as a 
transfection control. Real-time PCR showed that Tet2-/- NPCs had 
decreased NeuroD1 mRNA levels (n = 3, p<0.05), and decreased Gfap mRNA levels (n
= 3, p<0.05) upon differentiation. The relative mRNA levels were in comparison with 
Gapdh mRNA.  
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CHAPTER 
CONCLUSIONS AND FUTURE DIRECTIONS 
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        Studies using different Tet2 knock-out animal models revealed that Tet2 loss alters 
the epigenetic landscape with decreased 5hmC and global hypermethylation of the DNA, 
increases HSC self-renewal and myeloid progenitor expansion with skewed 
differentiation toward monocytic lineages, leading to the pathogenesis of myeloid 
malignancies84. Identification of critical novel partners of TET2, and unveiling the 
functional significance of their interactions may provide valuable insights into the 
mechanisms that underlie critical roles of TET2 in the tumorigenesis of many cancers.  
        In this dissertation I investigated whether Tet2 loss leads to various types of 
hematological malignancies other than myeloid malignancies, and what cellular 
phenotypes Tet2-/- mice may have. Because clinical studies have reported the 
haploinsufficient role of TET2 in leukemic patients, it was important to understand if 
Tet2 loss in mice causes leukemic disease phenotypes as in humans. Using a two-year 
follow-up investigation, I found that Tet2-/- mice also develop lymphoid malignancies, 
consistent with TET2 mutant patients with lymphoid disorders. Hence, additional genetic 
lesions is at least in part required for Tet2 loss induced hematological malignancies.  
        Depending on the methods in genome analysis, diverse Tet2-/- genome landscapes 
can be depicted via next-generation exome sequencing and aCGH.  These techniques 
make it possible to sequence all the protein-coding genes and detect chromosome 
abnormalities. Therefore, it was feasible to propose understanding if Tet2 is required for 
maintaining genome integrity. By using exome sequencing, several “driver mutations” 
were identified in Tet2 loss background. Because of the biological instability of 5mC, it 
is plausible to assume that these mutation sites are close to Tet2-dependent 5hmC sites. 
Indeed, significant correlations between mutation sites and Tet2-dependent 5hmC sites 
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were found. Next, if Tet2 regulates genome integrity, relying on its enzymatic activity, 
mutation sites would be expected to be located only at cytosine. Then, it would be  
important to understand what are the TET2 protein interactors that participate in Tet2-
mediated DNA repair mechanism. The present finding that there is a TET2 and MSH6 
interaction, strengthen the concept of mutator phenotypes in Tet2-/- mice and TET2 
knockdown cell lines. With these observations, a model was proposed that explains how 
Tet2 can regulate genome integrity through interacting with MSH6. Chapter II 
determined that: 
 ~8% of Tet2-/- mice develops lymphoid malignancies of both T- and B-cell origin, 
although myeloid malignancies dominates. 
  Whole-exome sequencing identified recurrent mutations from Tet2-/- tumors of 
each cell origin, such as Notch1 mutations in the T-cell leukemia/lymphoma. 
  Using protein purification and mass spectrometry, I found that TET2 associates 
with MSH6, a key protein involved in DNA-mismatch repair (MMR).  
  Tet2-depleted HeLa, and NIH3T3 cells display elevated spontaneous mutation 
frequency, characteristic of MMR-deficient cells. 
         
        Also, I characterized Tet2 and 5hmC in mouse cerebellum and hippocampus during 
postnatal development and aging. Tet2 regulates 5mC oxidation at NeruoD1 and Gfap 
promoter regions during aging, pointing to a critical role for Tet2 in adult neurogenesis. 
My study has great potential for improving the understanding of Tet2-mediated DNA 
demethylation in neurodevelopment and neurodegenerative disorders. Chapter III 
determined that:  
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 Tet2 is highly expressed in adult brain compared to postnatal P7 brain. 
  Loss of Tet2 leads to increased adult NPCs proliferation and decreased adult 
NPCs differentiation. 
  Tet2 regulates adult brain neurogenesis through 5mC oxidation of NeuroD1 and 
Gfap promoter regions. 
        Together, the observations presented here reveal that Tet2 is involved in different 
regulatory mechanisms in different systems. In the hematological system, Tet2 serves as 
a tumor suppressor gene to protect the genome from being mutated and is also dependent 
on the interaction with MSH6 during DNA damage repair. In the nervous system, it is 
also clear that Tet2 regulates 5hmC dynamics at its specific downstream loci, and 
subsequently has an effect on adult neurogenesis. A better understanding of Tet2 
regulatory network including TET2-binding protein complex and Tet2-binding DNA 
sequences may prove to be essential for pharmaceutical research, with the goal, to 
address Tet2–related diseases.  
        Future research on Tet2 in the hematological system will be focused on several 
important aims: 1) providing a detailed characterization of hematological malignancies of 
Tet2-/- mice; 2) determining when mutations occur during cell differentiation; 3) mapping 
the minimum binding regions between TET2 and MSH6; 4) crossing Tet2-/- and Msh6-/- 
mice to elucidate the relationship between TET2 and MSH6. Additional questions to be 
addressed include whether the association between TET2 and MSH6 is disrupted in Tet2-
deficient mice; and if genomic instability is a “driver” or a “consequence” of malignant 
transformation.  The latter could be clarified by exome sequencing of premalignant WT, 
Tet2+/- and Tet2-/- hematopoietic stem/progenitor cells.  
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 For understanding the role of Tet2 in neurogenesis, it makes sense to evaluate 
Tet2 in the context of spatial learning and memory based on the present findings of 
impaired neurogenesis in Tet2 mutants, which may greatly influence learning and 
memory. I can also investigate the epigenetic changes (5mC and 5hmC) of Tet2 
downstream target genes and examine their transcriptional regulation and involvement in 
neurogenesis. The definitive role of Tet2 loss-induced adult-neurogenesis-defects should 
be investigated using Tet2 conditional knockout mice in which tissue/cell-specific 
elimination would help to better understand the biological functions of Tet2 in the 
nervous system. 
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